


MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

[2nd Edition]



Ministry of Health Malaysia



Academy of Medicine Malaysia



Malaysian Thoracic Society

These are revised and updated Clinical Practice Guidelines (CPG) on the Management of Chronic Obstructive Pulmonary Disease (COPD). These CPG supersede the previous CPG on Management of COPD (1998).

STATEMENT OF INTENT

These guidelines are meant to be a guide for clinical practice, based on the best available evidence at the time of development. Adherence to these guidelines may not necessarily guarantee the best outcome in every case. Every health care provider is responsible for the management of his/her unique patient based on the clinical presentation of the patient and the management options available locally.

REVIEW OF THE GUIDELINES

These guidelines were issued in November 2009 and will be reviewed in November 2013 or sooner if new evidence becomes available.

CPG Secretariat
Health Technology Assessment Section
Medical Development Division
Ministry of Health Malaysia
4th Floor, Block E1, Parcel E
62590 Putrajaya

The electronic version is available on the following websites:

<http://www.moh.gov.my>

<http://www.acadmed.org.my>

<http://www.mts.org.my>

PREFACE

Chronic Obstructive Pulmonary Disease (COPD) is a common illness associated with major morbidity and high mortality throughout the world. It is the fourth leading cause of death in the United States¹ and is projected to rank fifth by 2020 in terms of burden of disease worldwide, according to a study by the World Bank and World Health Organization.² Yet COPD is relatively unknown to the public and often ignored by health policy makers and government officials.

In 1998, the Malaysian Thoracic Society with the support of the Academy of Medicine of Malaysia and Ministry of Health of Malaysia in their efforts to create awareness about the disease and improve patient care, initiated the publication of COPD management guidelines to be used as a reference for medical practitioners.³ The working group comprised 10 respiratory specialists who were working in government hospitals, teaching institutions and private medical facilities. The recommendations made were mainly based on the published literature available at the time after thorough assessment by the assigned member or members of the working group and discussion at several face-to-face meetings. The evidence used for the recommendations was then graded according to its level of strength with some recommendations made based on the consensus agreement of members of the working group. Notwithstanding, the concept of evidence-based medicine was just emerging at that time. After more than a decade, with advancement of care made and with the publication of many important large-scale, randomised studies which added new dimension to the management of COPD, the time had come for these guidelines to be reviewed and updated. An updated set of CPG will ensure that the recommendations for the management of COPD in Malaysia are current. We would like to emphasise the importance of (1) early diagnosis through targeted spirometry and early intervention including smoking cessation even in mild COPD; (2) improving dyspnoea and activity limitation in stable COPD using up-to-date evidence-based treatment algorithms; and (3) preventing and managing acute exacerbations, particularly in more severe COPD.

I sincerely hope this revised edition of the CPG for the Management of COPD will be fully utilised by all relevant healthcare professionals and will benefit patients suffering from COPD. I would like to express my heartfelt gratitude to everyone who was involved in the development of these guidelines and especially to the working group members for their enthusiasm, relentless effort and immense contribution.



Professor Dr. Liam Chong-Kin
Chairman
COPD CPG Working Group

References:

1. National Heart, Lung, and Blood Institute. Morbidity And Mortality Chartbook On Cardiovascular, Lung And Blood Diseases. Bethesda, Maryland: Us Department Of Health And Human Services, Public Health Service, National Institute Of Health. Accessed At:<http://www.nhlbi.nih.gov/resources/docs/cht-book.htm>; 2004.
2. Lopez Ad, Shibuya K, Rao C, Et Al. Chronic Obstructive Pulmonary Disease: Current burden and future projections. *Eur Respir J* 2006; 27:397-412.
3. Guidelines In The Management Of Chronic Obstructive Pulmonary Disease-A Consensus Statement Of The Ministry Of Health Of Malaysia, Academy Of Medicine Of Malaysia And Malaysian Thoracic Society. *Med J Malaysia* 1999; 54:387-400.

GUIDELINES DEVELOPMENT AND OBJECTIVES

Guidelines Development

Respiratory physicians working in government hospitals, academic institutions and private medical facilities; an emergency medicine physician and primary care physicians from a government health clinic, an academic institution and private general practice were invited to be members of the guidelines development working group.

The previous edition of the CPG on the Management of COPD (1998) was used as the basis for the development of this present set of guidelines. Members of the working group were divided into smaller groups comprising 2 to 5 members who were assigned to prepare documents on the following sections: (1) definition, classification of severity and mechanism of COPD; (2) burden of COPD; (3) risk factors; (4) assessment and monitoring of disease; (5) reducing risk factors; (6) managing stable COPD - pharmacological treatments; (7) managing stable COPD - non-pharmacological treatments; (8) managing exacerbations; and (9) translating guidelines recommendations to the context of primary care.

Members responsible for each section were tasked to ensure that the relevant literature was adequately searched, retrieved, critically appraised and accurately presented. Literature search was carried out at electronic databases which included PUBMED, Medline and Cochrane Database of Systemic Reviews. The full text of reference articles quoted in these guidelines was carefully studied. In addition, the reference lists of relevant articles retrieved were searched to identify other studies. Other guidelines on the management of COPD that were referred to included the "Guidelines of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease" (2008) and the "Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease"(2007).

Each section leader presented his/her section of the proposed guidelines at several meetings where all members of the working group met and participated in the discussion. The final draft of these guidelines inclusive of recommendations was the result of agreement by the majority, if not all, members of the working group at such meetings as well as through e-mail discussions in between the meetings. Throughout the development of these guidelines, a total of six meetings were held from 10 January 2009. In situations where the evidence was insufficient or lacking, the recommendations made were by consensus of the working group.

In these guidelines, statements are supported by evidence which is graded using the United States/Canadian Preventive Services Task Force Level of Evidence scale with the level of evidence indicated in parentheses after the relevant statement, while the grading of recommendations was based on modified Scottish Intercollegiate Guidelines Network's (SIGN) Grade of Recommendations which is also shown in parentheses.

The draft guidelines were sent for external review. The draft guidelines were also posted on the Ministry of Health Malaysia website for comments and feedback. These guidelines were presented to the Technical Advisory Committee for Clinical Practice Guidelines and the Health Technology Assessment and Clinical Practice Guidelines Council, Ministry of Health Malaysia for review and approval.

Objectives

The main objective of these guidelines is to provide up-to-date evidence-based recommendations to assist health care providers in the identification, diagnosis and optimal management of people with COPD.

Clinical Questions

The clinical questions of these guidelines are:

1. How can COPD be prevented?
2. How is COPD diagnosed?
3. How can people with COPD be optimally managed?

Target Population

These guidelines are applicable to all adults with COPD.

Target Groups/Users

These guidelines are intended for all health care professionals involved in managing patients with COPD who include: respiratory physicians, general physicians, geriatricians, family medicine specialists, emergency medicine physicians, medical officers, general practitioners, assistant medical officers, pharmacists, respiratory nurse educators, nurses, physiotherapists and public health personnel.

CLINICAL INDICATORS FOR QUALITY MANAGEMENT

Proportion of people with COPD treated for acute exacerbation (with antibiotics and/or systemic corticosteroids and/or requiring hospitalisation)

Numerator : Number of episodes of acute exacerbation treated in one year[#]

Denominator : Total number of patients with COPD on treatment in one year

([#]It is necessary to distinguish patients with moderate stable COPD from those with severe or very severe stable COPD)

The optimum achievable standard:

For patients with

- Moderate COPD : ≤ 1 exacerbation per patient per year
- Severe or very severe COPD: ≤ 1.5 exacerbations per patient per year

These standards are arrived at based on the results of several recent large randomised controlled trials. In the INSPIRE study involving patients with severe and very severe COPD ($FEV_1 < 50\%$ predicted), the exacerbations rates were 1.28 per year in patients treated with salmeterol/fluticasone combination and 1.32 per year in patients on tiotropium.^{1 (Level 1)} In the TORCH study involving patients with moderate to very severe COPD ($FEV_1 < 60\%$ predicted), treatment with salmeterol, fluticasone and salmeterol/fluticasone combination was associated with exacerbation rates of 0.97, 0.93 and 0.85, respectively compared to 1.13 in patients on placebo.^{2 (Level 1)} In the UPLIFT study involving patients with moderate to very severe COPD ($FEV_1 \leq 70\%$ predicted) already on a regular β_2 -agonist with or without inhaled corticosteroids, treatment with tiotropium or placebo was associated with exacerbation rates of 0.73 and 0.85 per patient-year, respectively.^{3 (Level 1)}

REFERENCES:

1. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. *Am J Respir Crit Care Med* 2008; 177:19-26.
2. Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. *N Engl J Med* 2007; 356:775-789.
3. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. *N Engl J Med* 2008; 359:1543-1554.

TABLE OF CONTENTS

PREFACE	i
GUIDELINES DEVELOPMENT AND OBJECTIVES	ii
CLINICAL INDICATORS FOR QUALITY MANAGEMENT	iii
CLINICAL PRACTICE GUIDELINES WORKING GROUP	vi
EXTERNAL REVIEWERS	vii
SECTION 1 DEFINITION, CLASSIFICATION OF SEVERITY AND PATHOPHYSIOLOGY	1
1.1 Definition	1
1.2 Airflow Limitation in COPD	1
1.3 Spirometric Classification of COPD Severity	1
1.4 Assessment of COPD Severity	3
1.5 Pathology, Pathogenesis and Pathophysiology	5
SECTION 2 COPD : EPIDEMIOLOGY AND DISEASE BURDEN	6
SECTION 3 RISK FACTORS	8
3.1 Introduction	8
3.2 Genes	8
3.3 Exposure to Particles	8
3.4 Lung Growth and Development	9
3.5 Oxidative Stress	9
3.6 Gender	9
3.7 Infection	9
3.8 Socioeconomic Status	10
SECTION 4 ASSESSMENT AND MONITORING	11
4.1 Initial Diagnosis	11
4.2 Assessment of Symptoms	11
4.3 Medical History	11
4.4 Physical Examination	12
4.5 Measurement of Lung Function	12
4.6 Bronchodilator Reversibility Testing	12
4.7 Assessment of COPD Severity	12
4.8 Additional Investigations	12
4.9 Differential Diagnosis	13
4.10 Ongoing Monitoring and Assessment	14
SECTION 5 REDUCING RISK FACTORS	16
5.1 Introduction	16
5.2 Smoking Prevention	16
5.3 Smoking Cessation	16
5.4 Five Step Programme for Intervention (5A)	17
5.5 Counselling	18
5.6 Pharmacotherapy	18
5.7 Occupational Exposure	18
5.8 Indoor and Outdoor Air Pollution	18
5.9 Steps for Health Care Providers/Patients	19

SECTION 6	MANAGING STABLE COPD : EDUCATION AND PHARMACOLOGICAL TREATMENTS	20
6.1	Objectives of Managing Stable COPD	20
6.2	Patient Education	20
6.3	Influenza Vaccination	21
6.4	Pneumococcal Vaccination	21
6.5	Treatment Strategy: Pharmacological and Non-pharmacological Treatments	21
SECTION 7	MANAGING STABLE COPD : NON-PHARMACOLOGICAL TREATMENTS	28
7.1	Pulmonary Rehabilitation in COPD	28
7.2	Domiciliary Oxygen Therapy for COPD	29
7.3	Nutrition in COPD	30
7.4	Lung Volume Reduction for COPD	30
7.5	Lung Transplantation	31
7.6	COPD and Surgery	31
SECTION 8	MANAGING EXACERBATIONS OF COPD	33
8.1	Introduction	33
8.2	Definition of Acute Exacerbation of COPD	33
8.3	Morbidity and Mortality Associated with Acute Exacerbations of COPD	33
8.4	Causes of Acute Exacerbations of COPD	33
8.5	Diagnosis and Assessment of Severity	33
8.6	Differential Diagnoses	35
8.7	Managing Acute Exacerbations of COPD	35
8.8	Home Management	36
8.9	Hospital Management	36
8.10	Management of Severe but Not Life Threatening Exacerbations of COPD in the Emergency Department or the Hospital	42
8.11	Non-invasive Ventilation	43
8.12	Invasive Mechanical Ventilation	43
8.13	Hospital Discharge	44
8.14	Follow Up	44
SECTION 9	TRANSLATING GUIDELINES RECOMMENDATIONS TO THE CONTEXT OF PRIMARY CARE	45
9.1	Introduction	45
9.2	Early Diagnosis	45
9.3	Smoking Cessation	45
9.4	Spirometry	45
9.5	Long Term Management	45
9.6	When to Refer to Hospital-Based Specialists?	46
GLOSSARY OF TERMS		47
ACKNOWLEDGEMENTS		48
DISCLOSURE STATEMENT		48
SOURCES OF FUNDING		48
REFERENCES		49

CLINICAL PRACTICE GUIDELINES WORKING GROUP

CHAIRMAN

Professor Dr. Liam Chong-Kin

Senior Consultant Chest Physician, Pusat Perubatan Universiti Malaya, Kuala Lumpur

MEMBERS (*alphabetical order*)

Dato' Dr. Abdul Razak Muttalif

Senior Consultant Chest Physician
Hospital Pulau Pinang
Pulau Pinang

Datin Dr. Aziah Ahmad Mahayiddin

Senior Consultant Chest Physician
Institut Perubatan Respiratori
Hospital Kuala Lumpur
Kuala Lumpur

Dr. Che' Wan Aminud-din bin Hashim

Chest Physician
Hospital Universiti Sains Malaysia
Kubang Kerian
Kelantan

Assoc. Prof. Dr. Fauzi Mohd. Anshar

Consultant Chest Physician
Pusat Perubatan Universiti Kebangsaan Malaysia
Kuala Lumpur

Dr. George Gomez

General Practitioner
Pertama Medical Associates
Johor Bharu

Dato' Dr. George K. Simon

Senior Consultant Chest Physician
Hospital Sultanah Bahiyah
Alor Setar

Assoc. Prof. Dr. How Soon Hin

Consultant Chest Physician
International Islamic University Malaysia
Hospital Tengku Ampuan Afzan
Kuantan

Prof. Dr. Khoo Ee Ming

Consultant Primary Care Physician
Pusat Perubatan Universiti Malaya
Kuala Lumpur

Dr. Leong Oon Keong

Senior Consultant Chest Physician
Leong Oon Keong Chest & Medical Clinic Sdn. Bhd.
Ipoh

Dr. Mohd Idzwan Zakaria

Emergency Medicine Physician
Pusat Perubatan Universiti Malaya
Kuala Lumpur

Assoc. Prof. Dr. Pang Yong Kek

Consultant Chest Physician
Pusat Perubatan Universiti Malaya
Kuala Lumpur

Prof. Dr. Richard Loh Li Cher

Consultant Chest Physician
Kolej Perubatan Pulau Pinang
Pulau Pinang

Dr. Rohaya Abdullah

Family Medicine Specialist
Klinik Kesihatan Masai
Johor Bahru

Assoc. Prof. Dr. Roslina A Manap

Consultant Chest Physician
Pusat Perubatan Universiti Kebangsaan Malaysia
Kuala Lumpur

Assoc. Prof. Dr. Tengku Saifudin Tengku Ismail

Consultant Chest Physician
Universiti Teknologi MARA
Hospital Selayang
Selangor

Dr. Wong Kai Fatt

General Practitioner
LW Medical Associates
Kuala Lumpur

Dr. Yap Boon Hung

Consultant Chest Physician
Hospital Tung Shin
Kuala Lumpur

Dato' Dr. Zainudin Md Zin

Senior Consultant Chest Physician
Hospital Pakar Damansara
Petaling Jaya

EXTERNAL REVIEWERS *(alphabetical order)*

The following external reviewers provided feedback on the draft.

Dr. Ashoka Menon

Senior Consultant Chest Physician
Pusat Perubatan Sime Darby
Subang Jaya

Associate Professor Ayiesah Hj Ramli

Physiotherapy Programme Coordinator
Faculty of Allied Health Sciences
Universiti Kebangsaan Malaysia
Kuala Lumpur

Ms P. Devashanti

Pharmacist
Pusat Perubatan Universiti Malaya
Kuala Lumpur

Associate Professor Dr Fanny Ko Wai-San

Department of Medicine and Therapeutics
The Chinese University of Hong Kong
Hong Kong

Dr. Hooi Lai Ngoh

Senior Consultant Chest Physician
Public Specialist Centre
Georgetown

Dr. Jamalul Azizi Abdul Rahman

Head of Department & Consultant Respiratory Physician
Department of Respiratory Medicine
Hospital Queen Elizabeth
Kota Kinabalu

Dr. Kuppusamy Iyawoo

Senior Consultant Chest Physician
Hospital Assunta
Petaling Jaya

Puan Nurhayati Mohd. Nur

Clinical Nurse Specialist in Respiratory Medicine
Nursing Officer
Pusat Perubatan Universiti Malaya
Kuala Lumpur

Dr. Wong Wing Keen

Senior Consultant Chest Physician
Pusat Perubatan Sunway
Petaling Jaya

Dr. Zariah Mohd Zain

Disease Control Division
Ministry of Health Malaysia
Putrajaya

SECTION 1 DEFINITION, CLASSIFICATION OF SEVERITY AND PATHOPHYSIOLOGY

1.1 Definition

Chronic obstructive pulmonary disease (COPD), a preventable and treatable respiratory disorder largely caused by smoking, is characterised by progressive, partially reversible airflow obstruction and lung hyperinflation with significant extrapulmonary (systemic) manifestations^{1 (Level II-2)} and co-morbid conditions^{2 (Level II-3)} all of which may contribute to the severity of the disease in individual patients.

The co-morbid conditions associated with COPD include ischaemic heart disease; osteopenia, osteoporosis and bone fractures; cachexia and malnutrition; normochromic normocytic anaemia; skeletal muscle wasting and peripheral muscle dysfunction; diabetes mellitus; sleep disorders; cataracts and glaucoma; lung cancer; and anxiety and depression both of which increase in incidence with disease severity.^{1-9 (Level II-2)}

1.2 Airflow Limitation in COPD

The chronic airflow limitation in COPD is due to a mixture of small airway disease (obstructive bronchiolitis) and lung parenchymal destruction (emphysema), the relative contributions of which vary from individual to individual. Airflow limitation, associated with an abnormal inflammatory reaction of the lung to noxious particles or gases, the most common of which worldwide is cigarette smoke, is usually progressive, especially if exposure to the noxious agents persists.

Airflow limitation is best measured by spirometry, the most widely available and reproducible test of lung function.

1.3 Spirometric Classification of COPD Severity

Objective demonstration of airflow obstruction by spirometry is essential for the diagnosis of COPD. Spirometry also provides an assessment of the severity of pathological changes in COPD. Spirometry should be performed after an adequate dose of an inhaled bronchodilator (e.g., 400 µg of salbutamol)^{10 (Level III)} in order to minimise variability.

For diagnosis and severity assessment of COPD, a post-bronchodilator FEV₁/FVC ratio of < 0.70 and post-bronchodilator FEV₁ measurement, respectively are recommended.^{11 (Level III)} A simple but yet to be clinically validated classification of COPD severity into four stages based on spirometric cut-points (FEV₁ < 80, 50, or 30% predicted) is recommended (Table 1-1).^{11 (Level III)}

Table 1-1 Classification of COPD Severity¹¹ (Level III)

COPD stage	Severity	Post-bronchodilator spirometric values ¹¹ (Level III)	Symptoms that may be present
I	Mild	FEV ₁ /FVC < 0.70 FEV ₁ ≥ 80% predicted	Chronic cough and sputum production may be present. At this stage, the individual is usually unaware that his or her lung function is abnormal.
II	Moderate	FEV ₁ /FVC < 0.70 50% ≤ FEV ₁ < 80% predicted	Dyspnoea typically on exertion, cough and sputum production sometimes also present. This is the stage at which patients usually seek medical attention because of chronic respiratory symptoms or an exacerbation of COPD.
III	Severe	FEV ₁ /FVC < 0.70 30% ≤ FEV ₁ < 50% predicted	Greater dyspnoea, reduced exercise capacity, fatigue, and repeated exacerbations that almost always have an impact on the patient's quality of life.
IV	Very severe	FEV ₁ /FVC < 0.70 FEV ₁ < 30% predicted or FEV ₁ < 50% predicted plus chronic respiratory failure	Respiratory failure may lead to cor pulmonale with signs which include elevation of the jugular venous pressure and pitting ankle oedema. At this stage, quality of life is markedly impaired and exacerbations may be life-threatening.

FEV₁: forced expiratory volume in one second; FVC: forced vital capacity; respiratory failure: arterial partial pressure of oxygen (PaO₂) less than 8.0 kPa (60 mmHg) with or without arterial partial pressure of CO₂ (PaCO₂) greater than 6.7 kPa (50 mmHg) while breathing air at sea level.

1.4 Assessment of COPD Severity

The relationship between the degree of airflow limitation based on spirometry and COPD symptoms is not perfect. The impact of COPD on an individual patient depends not just on the degree of airflow limitation, but also on the severity of symptoms - especially breathlessness and decreased exercise capacity. COPD management decisions for the individual patient should therefore not be based solely on spirometry results, but also on the severity of dyspnoea and disability^{12 (Level III)} which can be assessed using the Modified Medical Research Council (MMRC) dyspnoea scale (Table 1-2)^{13 (Level III)} which reflects overall disease impact among COPD patients than FEV₁.

A multidimensional grading system of disease severity, the BODE index [body mass index (BMI), airflow obstruction, dyspnoea and exercise capacity], better predicts survival in COPD patients than FEV₁.^{14 (Level II-2)} A simple but yet to be validated classification of COPD severity can be based on both spirometry and symptoms (Table 1-3) bearing in mind that there may be poor correlation between spirometric measures of lung function and symptoms in individual patients.

Table 1-2 The Modified Medical Research Council (MMRC) Dyspnoea Scale^{13 (Level III)}

Grade of dyspnoea	Description
0	Not troubled by breathlessness except on strenuous exercise
1	Shortness of breath when hurrying on the level <i>or</i> walking up a slight hill
2	Walks slower than people of the same age on the level because of breathlessness <i>or</i> has to stop for breath when walking at own pace on the level
3	Stops for breath after walking about 100 m <i>or</i> after a few minutes on the level
4	Too breathless to leave the house <i>or</i> breathless when dressing or undressing

To determine the appropriate treatment, a comprehensive assessment of COPD severity should take into account the patient's level of symptoms and the severity of the spirometric abnormality; the presence of complications such as respiratory failure, cor pulmonale and weight loss; as well as the presence of extrapulmonary effects of COPD and co-morbidities. Besides spirometry, the overall assessment of a COPD patient should also include the assessment of the patient's BMI, the patient's dyspnoea (such as using the MMRC dyspnoea scale),^{13 (Level III)} exercise capacity (such as using the 6-minute walk test),^{15 (Level III)} and co-morbidities.

Table 1-3 Classification of COPD Severity Based on Spirometric Impairment and Symptoms
(adapted from references 11 and 12)^(Level III)

COPD stage	Severity	Classification by post-bronchodilator spirometric values	Classification by symptoms and disability
I	Mild	FEV ₁ /FVC < 0.70 FEV ₁ ≥ 80% predicted	Shortness of breath when hurrying on the level <i>or</i> walking up a slight hill (MMRC 1)
II	Moderate	FEV ₁ /FVC < 0.70 50% ≤ FEV ₁ < 80% predicted	Walks slower than people of the same age on the level because of breathlessness; <i>or</i> stops for breath after walking about 100 m or after a few minutes at own pace on the level (MMRC 2 to 3)
III	Severe	FEV ₁ /FVC < 0.70 30% ≤ FEV ₁ < 50% predicted	Too breathless to leave the house <i>or</i> breathless when dressing or undressing (MMRC 4)
IV	Very severe	FEV ₁ /FVC < 0.70 FEV ₁ < 30% predicted <i>or</i> FEV ₁ < 50% predicted plus chronic respiratory failure	Presence of chronic respiratory failure <i>or</i> clinical signs of right heart failure

**Should there be disagreement between FEV₁ and symptoms, follow symptoms*

FEV₁: forced expiratory volume in one second; FVC: forced vital capacity; respiratory failure: arterial partial pressure of oxygen (PaO₂) less than 8.0 kPa (60 mmHg) with or without arterial partial pressure of CO₂ (PaCO₂) greater than 6.7 kPa (50 mmHg) while breathing air at sea level.

After confirmation of diagnosis by spirometry, the treatment for the individual patient may be based on symptoms with the recognition that symptoms may be made worse by co-morbid conditions which should also be appropriately treated if present.

1.5 Pathology, Pathogenesis and Pathophysiology

The pathological changes in COPD, which include chronic inflammation and structural changes resulting from repeated injury and repair due to inhaled cigarette smoke and other noxious particles, are found in the proximal airways, peripheral airways, lung parenchyma, and pulmonary vasculature.^{16 (Level II-2)} The chronic inflammation in COPD is characterised by an increase in the numbers of neutrophils (in the airway lumen), macrophages (in the airway lumen, airway wall, and parenchyma), and CD8+ lymphocytes (in the airway wall and parenchyma).^{17 (Level II-2)} The cells and mediators involved in the inflammatory processes in COPD and in asthma are different which explains the differences in physiological changes, symptoms and response to treatment in these two diseases.

These pathological changes lead to mucus hypersecretion,^{18 (Level II-2)} expiratory airflow limitation with dynamic small airway collapse causing air trapping and lung hyperinflation, gas exchange abnormalities, and progressive pulmonary hypertension that may lead to cor pulmonale.^{19 (Level II-2)}

There is further amplification of the inflammatory response in the airways during exacerbations, which may be triggered by bacterial or viral infections or by environmental pollutants.

In general, the inflammatory and structural changes in the airways increase with disease severity and persist on smoking cessation.


Recommendations: Diagnosis and Assessment of Severity

1. Spirometry is essential for the diagnosis of COPD and is useful for assessment of the severity of airflow obstruction. *[Grade C]*
2. Management decisions should be guided by the overall assessment of the patient which should include symptoms, exercise capacity as well as the presence of co-morbidities and complications, in addition to spirometry. *[Grade C]*

SECTION 2 COPD : EPIDEMIOLOGY AND DISEASE BURDEN

COPD prevalence, morbidity, and mortality vary across the world and across different ethnic groups within countries. The prevalence and burden of COPD are projected to increase in the coming decades due to continued exposure to COPD risk factors and the changing age structure of the world's population.^{20-22 (Level II-3)} According to WHO estimates in 2007, 210 million people have COPD worldwide with 80 million of them experiencing moderate to severe chronic disease.^{23 (Level II-3)} COPD was ranked as the twelfth leading cause of disability in 1990, but it is projected to rank fifth in 2020, behind ischaemic heart disease, major depression, traffic accidents and cerebrovascular disease as a leading cause of disability.^{24 (Level II-3)} It is second only to heart disease as a cause of disability that forces people to stop working.^{25 (Level II-3)} The number of deaths from COPD have increased more than 60% over the last 20 years, and more than 95% of all COPD-related deaths occur in people older than age 55 (**Figure 2-1**).^{26 (Level II-3)} COPD will become the third leading cause of death worldwide by 2030.^{27 (Level III)}

Figure 2-1: Age Standardised COPD Mortality Rate by WHO Region




A regions: developed countries in North America, Western Europe, Japan, Australia, and New Zealand; **AMRO BD:** developing countries in the Americas; **EURO BC:** developing countries in Europe; **EMRO:** Eastern Mediterranean and North Africa; **SEARO:** South-east Asia; **WPRO:** Western Pacific; **AFRO:** Sub-Saharan Africa.

These statistics are likely to underestimate COPD as a cause of death due to the imprecise and variable definitions of COPD that complicate the quantification of its mortality and morbidity.^{28 (Level II-3), 29 (Level III)} In addition, COPD is more likely to be reported as a contributory rather than underlying cause of death or morbidity, or may not be reported at all.^{30, 31 (Level III)} In Asia-Pacific countries where tobacco smoking and indoor air pollution are highly prevalent the rise of COPD incidence is particularly dramatic contributing to a significant disease burden.^{32 (Level III)} Data from a WHO/World Bank study were used to extrapolate a COPD prevalence figure of 3.8% for the entire Asian population,^{24 (Level III)} but recent studies suggest that COPD is a more significant problem in the region than has been previously realised.

Two major studies conducted in Japan^{33 (Level II-2)} and Korea^{34 (Level II-2)} more recently showed a COPD prevalence of 8.55% and 7.5% respectively. The prevalence of COPD in Asia-Pacific has been estimated indirectly through a risk factor prevalence model, which was mainly driven by varying smoking rates and levels of air pollution.^{32 (Level III)} The prevalence of moderate to severe COPD in adults aged 30 years or above in the Asia-Pacific region was estimated to be at approximately 6.3% and for Malaysia at 4.55% (**Figure 2-2**).

Figure 2-2: Model Projections of Moderate-Severe COPD in Population Aged ≥ 30 Years



Consistent with the findings of WHO Global Burden of Disease study,^{24 (level II-3)} both mortality and morbidity rates for COPD in the Asia-Pacific region were reported to be higher in men than in women and increased with increasing age.^{35 (Level III)} COPD-related illness was higher in men, with rates of 32.6 to 334^{26 (Level II-3)} per 10,000 people, compared with rates of 21.2 to 129 per 10,000 for women.^{36 (level III)} Chronic respiratory disease including COPD is responsible for 7% of the total Disability-Adjusted Life Years (DALYs) in Malaysia and is ranked fifth as the leading cause of disease burden.^{37 (Level III)} The burden of COPD in males is almost three times that of females. The per capita burden of disease increases with age both in males and females where it is predominantly due to COPD in males, while in females it is related to other respiratory diseases.^{37 (Level III)} In a survey by the Southeast Asia Tobacco Control Alliance (SEATCA) in Malaysia in 2006, 77% of the health economy burden with the highest growth projected health care cost (2004-2010) among the three major tobacco-related diseases in Malaysia is contributed by COPD.^{37 (Level III)}

SECTION 3 RISK FACTORS

3.1 Introduction

Cigarette smoking is the best known and most studied risk factor for COPD. About 15% of smokers develop COPD.^{38 (Level II-2)} However, tobacco smoke is the risk factor for as much as 90% of the cases of COPD.^{39 (Level III)} Understandably, tobacco smoke cannot be the only risk factor for COPD as non-smokers may also develop the disease. Other risk factors for COPD are varied and are listed in **Table 3-1**.

Table 3-1 Risk Factors for COPD

Genes
Exposure to particles
• Tobacco smoke
• Organic and inorganic occupational dusts
• Indoor air pollution from heating and cooking with biomass in poorly ventilated dwellings
• Outdoor air pollution
Lung growth and development
Oxidative stress
Gender
Age
Respiratory infections
Socioeconomic status

3.2 Genes

Severe alpha-1 antitrypsin enzyme deficiency causes panlobular emphysema in both smokers and non-smokers. This rare hereditary disease is most commonly seen in individuals of Northern European origin.^{40 (Level II-2)} There have been inconsistent reports on the familial risk of airflow obstruction in smoking siblings of patients with severe COPD.^{41 (Level II-2)}

3.3 Exposure to Particles

• Tobacco smoke

Cigarette smoke causes COPD in susceptible individuals. The risk of COPD in smokers is dose-related.⁴² Pipe and cigar smokers have greater COPD morbidity and mortality rates than non-smokers, although their rates are lower than those for cigarette smokers.^{43 (Level III)} Environmental tobacco smoke also contributes to respiratory symptoms and COPD by increasing the lungs' total burden of inhaled particles and gases.^{44,45 (Level II-2)} Pregnant women are advised to stop smoking as tobacco smoke poses a risk to the foetus by affecting lung growth and development in utero.^{46 (Level II-3)}

• Occupational dusts and chemicals

Occupational exposures are independently associated with the severity of airflow limitation, respiratory symptoms, and employment status in patients with COPD.^{47 (Level II-3)} These exposures include organic and inorganic dusts, chemical agents and fumes. Livestock farmers have an increased risk of chronic bronchitis, COPD and reduced FEV₁. Ammonia, hydrogen sulphide, inorganic dust and organic dust may be causally involved, but a role for specific biological agents cannot be excluded. Atopic farmers appear more susceptible to develop farming-related COPD.^{48 (Level II-3)}

- **Indoor air pollution**

Biomass and coal are the main sources of energy for cooking and heating in many communities in the Middle East, Africa and Asia.^{49,50 (Level III)} Wood, animal dung, crop residues and coal are burned in poorly functioning stoves, in poorly ventilated rooms and lead to very high levels of indoor air pollution, a well established risk factor of COPD in women.^{51-54 (Level II-2)}

- **Outdoor air pollution**

The role of outdoor air pollution in causing COPD is unclear, but appears to be small when compared with cigarette smoking. However, air pollution from motor vehicle emissions in cities is associated with a decrease in lung function.^{55 (Level II-3)}

3.4 Lung growth and development

Any factor that affects lung growth during gestation and childhood has the potential for increasing an individual's risk of developing COPD. A large study and meta-analysis confirmed a positive association between birth weight and FEV₁ in adulthood.^{56 (Level III)}

3.5 Oxidative stress

Oxidative stress results from an imbalance between oxidants (generated by phagocytes during mitochondrial electron transport, air pollutants, cigarette smoke, etc.) and antioxidants. Oxidative stress directly injures the lungs and initiates lung inflammation which plays a role in the pathogenesis of COPD.^{57 (Level III)}

3.6 Gender

The role of gender in determining COPD risk remains unclear. Some studies have suggested that women are more susceptible to the effects of tobacco smoke than men and raise concerns on the increasing number of female smokers in both developed and developing countries.^{58 (Level II-3)}

3.7 Infections

Infections, both viral and bacterial, may contribute to the pathogenesis, progression of COPD⁵⁹ and the bacterial colonisation associated with airway inflammation.^{60 (Level II-1)} Infection also plays a significant role in exacerbations associated with deterioration in lung function.^{61 (Level II-2)} **Figure 3-2** is a schematic diagram of the vicious circle hypothesis of the role of bacterial colonisation in the progression of COPD.^{62 (Level III)}

Figure 3-2: Vicious Circle Hypothesis⁶²




Image courtesy of Sanjay Sethi

3.8 Socioeconomic status

There is evidence that the risk of developing COPD is inversely related to socioeconomic status.⁶³
(Level II-2) It is not clear whether this pattern reflects exposures to indoor and outdoor air pollutants, crowding, poor nutrition, or other factors that are related to low socioeconomic status.^{64,65} (Level III)

SECTION 4 ASSESSMENT AND MONITORING

4.1 Initial Diagnosis

COPD is significantly underdiagnosed worldwide, including Malaysia.^{35,66 (Level III)} Many COPD patients present to their doctors with advanced disease at the time of diagnosis. Early diagnosis with successful smoking cessation interventions reduce the decline in lung function, and early intervention with effective treatment improves symptoms and health status.^{67,68 (Level II-2)}

A clinical diagnosis of COPD should be considered in any patient with a history of exposure to risk factors for the disease with symptoms of chronic cough, sputum production or dyspnoea.

The diagnosis should be confirmed by spirometry. A post-bronchodilator FEV₁/FVC ratio of less than 0.7 confirms the presence of airflow limitation that is not fully reversible and is currently widely accepted as diagnostic of COPD.^{69 (Level III)}

If spirometry is unavailable, clinical signs and symptoms, such as progressive shortness of breath and chronic cough with low peak expiratory flow rate, can be used to help with the diagnosis.^{70 (Level III)} Since peak expiratory flow readings have poor specificity,^{71 (Level II-2)} every effort should be made to refer the patient for spirometry to confirm the diagnosis.

4.2 Assessment of Symptoms

Dyspnoea is the hallmark symptom of COPD and the main reason patients seek medical attention. The dyspnoea is progressive over months or years and is persistent. As lung function deteriorates, the breathlessness interferes with patients' daily activities.

Cough is often the first symptom of COPD which may initially be intermittent but later present daily, often with chronic sputum production. Wheezing and chest tightness may also be present. Extrapulmonary effects such as weight loss, signs of cor pulmonale and other co-morbid conditions should also be identified and assessed.^{72 (Level III)} Psychiatric morbidity is common in advanced COPD.^{73 (Level III)}

COPD patients experience fluctuations in symptoms and general feelings of well-being which can vary from day to day.

4.3 Medical History

A thorough medical history should include the following:

- Current symptoms and the pattern of symptom development including severity of breathlessness, for example using the Modified Medical Research Council (MMRC) dyspnoea scale (**Table 1-2**)¹³
- Exposure to risk factors and possibilities for eliminating or reducing exposure
 - Smoking history
Quantification of tobacco consumption: total pack-years = (number of cigarettes smoked per day ÷ 20) x number of years of smoking
 - Occupational and environmental exposures to other lung irritants

- Impact of disease on psychosocial well being
- Past medical history including exacerbations and admissions for respiratory illnesses
- Family history of any respiratory disorder
- Presence of other co-morbidities such as cardiovascular disease, psychiatric illness, malignancy, osteoporosis and musculoskeletal disorders
- All current medical therapy and its appropriateness
- Social and family support available to the patient

4.4 Physical Examination

Physical examination is not usually diagnostic of COPD but is an important part of patient care. Physical signs of airflow limitation and air trapping (barrel chest, loss of cardiac and liver dullness, prolonged expiration, reduced breath sounds) are not usually present until the disease is already at an advanced stage. Physical examination may detect co-morbidities or other illnesses and detect the development of complications of COPD such as malnourishment and cor pulmonale.

4.5 Measurement of Lung Function

Spirometry is required to confirm the diagnosis of COPD and to assess the severity of the disease. Spirometry should be performed in people with exposure to risk factors who have chronic cough and sputum production even without dyspnoea as it may help identify patients earlier in the course of the disease.^{13,74 (Level III)} Peak flow measurements can detect airflow limitation but has poor specificity. The relationship between peak expiratory flow and FEV₁ is poor in COPD.^{75 (Level II-2)}

4.6 Bronchodilator Reversibility Testing

Bronchodilator testing is required to establish the best attainable lung function at that point of time. Response to a bronchodilator is considered significant if the change in FEV₁ is both at least 200 mL and 12% above the pre-bronchodilator FEV₁.^{76 (Level III)} If there is a marked response to bronchodilators, asthma should be considered. A proportion of COPD patients may show significant response to bronchodilators.^{77 (Level III)}

4.7 Assessment of COPD Severity

COPD severity is based on the patient's level of symptoms, the severity of spirometric abnormality based on FEV₁ and the presence of complications such as respiratory failure and cor pulmonale (Table 1-3).^{78 (Level III)} Multi-dimensional assessment of severity includes the BODE index^{79 (Level II-2)} and the locally developed SAFE index.^{80 (Level II-2)}

4.8 Additional Investigations

i. Six Minute Walk Test (6MWT)

This test measures the distance covered during six minutes and is a useful test of exercise capacity^{81 (Level III)} and provides prognostic information.^{82 (Level II-2)} Arterial oxygen desaturation can be measured with a pulse oximeter during walking.

ii. Chest Radiograph

A chest radiograph is valuable in excluding other diagnoses such as lung cancer, heart failure, bronchiectasis and tuberculosis. Radiological changes associated with COPD include the presence of hyperinflation (flattened diaphragm and increased lung volume), bullae and hyperlucency of the lungs. High resolution computed tomography scanning is not routinely recommended unless there is diagnostic uncertainty.

iii. Arterial Blood Gas Analysis

This should be performed in patients with $FEV_1 < 40\%$ predicted if they have low arterial oxygen saturation (less than 92% on pulse oximetry) or with clinical signs of respiratory failure or cor pulmonale as these patients may benefit from long term oxygen therapy at home.^{83 (Level III)}

iv. Full Blood Count

This detects underlying anaemia of chronic diseases. Polycythaemia can develop with chronic hypoxaemia.

v. Electrocardiography (ECG)

ECG is useful in detecting pulmonary hypertension in advanced disease and concurrent ischaemic heart disease.

vi. Alpha-1 Antitrypsin Deficiency Screening

This should be performed in young COPD patients (< 45 years old) or those who have a strong family history of the disease.

Other suggested investigations include fasting plasma glucose, serum albumin and serum fasting lipids to detect other common co-morbidities.

4.9 Differential Diagnoses

Other potential diagnoses in older patients presenting with progressive breathlessness are listed in **(Table 4-1)**. The major differential diagnosis is chronic asthma. In most instances, the diagnosis can be easily made **(Table 4-2)** but occasionally a clear distinction between asthma and COPD may not be possible clinically and physiologically, and it is assumed that both conditions co-exist in these patients.

Table 4-1 Main Differential Diagnoses of COPD

Bronchial asthma	Bronchiectasis
Congestive heart failure	Diffuse parenchymal lung disease
Pulmonary tuberculosis	Pulmonary vascular disease

Table 4-2 Clinical Differences Between Asthma and COPD

Clinical features	Asthma	COPD
Age of onset	Usually early childhood, but may have onset at any age	Usually > 40 years old
Smoking history	May be non-, ex- or current smoker	Usually > 10 pack-years
Atopy	Often	Infrequent
Family history	Asthma or other atopic disorders commonly present	Not a usual feature
Clinical symptoms	Intermittent and variable	Persistent and gradually progressive worsening
Cough	Nocturnal cough or on exertion	Morning cough with sputum
Sputum production	Infrequent	Often
Reversibility of airflow obstruction	Characteristic of asthma	Airflow limitation may improve but never normalises
Exacerbations	Common at all levels of severity except in mild disease	Increase in frequency with increasing severity of disease

4.10 Ongoing Monitoring and Assessment

COPD patients should be followed up regularly as COPD is usually a progressive disease with deterioration in clinical symptoms and lung function over time. Ongoing monitoring and assessment in COPD is vital to ensure that the goals of treatment are being met.

Follow-up visits should include evaluation of the following:

- Exposure to risk factors especially tobacco smoke. Ask about smoking and their willingness to stop (Refer to Section 5).
- Current symptoms and any new or worsening symptoms to suggest deterioration in lung function or development of complications. Consider the presence of concomitant conditions or co-morbidities.
- Physical examination to detect complications such as respiratory failure or cor pulmonale and other co-morbidities. Body weight and body mass index provide information on the nutritional status of the patient.
- Spirometry measurement especially if symptoms worsen. Active smokers and patients with frequent exacerbations are at risk of faster decline in lung function.
- Pharmacotherapy and other medical treatment. Assess the effectiveness of current regimen in controlling symptoms and any side effects from the medications. Ensure that patients are taking their medication at the right dose and frequency and inhaler techniques are correct. Issues regarding non-compliance to medications should be addressed.

- Exacerbation history. The frequency, severity and causes of exacerbations should be recorded. Severity can be estimated by the increased need for bronchodilator medication or systemic glucocorticosteroid requirements. Hospitalisations should be documented including the duration of stay and any use of invasive and non-invasive ventilation.
- Patient education. It is important for patients with COPD to understand the nature of their disease, risk factors for progression and strategies to help minimise symptoms.

Recommendations: Diagnosis and Assessment of Severity

1. The diagnosis of COPD should be confirmed by spirometry showing a post-bronchodilator FEV₁/FVC ratio of less than 0.7. *[Grade C]*
2. Assessment of COPD severity should be based on the severity of spirometric abnormality, the patient's symptoms, exercise capacity and the presence of co-morbidities and complications. *[Grade C]*

SECTION 5 REDUCING RISK FACTORS

5.1 Introduction

Identification, reduction, control and elimination of risk factors are important steps toward effective prevention and management of any disease. For COPD, these risk factors include tobacco smoke, occupational exposures, indoor and outdoor air pollution and irritants. Since cigarette smoking is the most commonly encountered risk factor for COPD worldwide, priority must be given to tobacco control programmes. Smoking prevention strategies and availability of smoking cessation services should be emphasised to encourage smoke-free lifestyles.

5.2 Smoking Prevention

Smoking prevention is the single most effective intervention to reduce the risk of developing COPD and stop its progression.^{68 (Level I)} This is endorsed by the international community with the establishment of the WHO Framework Convention on Tobacco Control (WHO FCTC) in 2005.

- Comprehensive tobacco control policies and programmes with clear, consistent, and repeated nonsmoking messages should be delivered through every feasible channel, including health care providers; community activities; schools; and radio, television, and the print media. Mandatory legal provision for pictorial health warnings on cigarette packs and packages is an efficient way to deliver clear, truthful anti-smoking messages directly to smokers.
- National and local campaigns should be undertaken to reduce exposure to tobacco smoke in public places. Such bans are proven to work, resulting in measurable gains in respiratory health.^{84 (Level I)}
- Smoking prevention programmes should target all ages, including young children, adolescents, young adults, and pregnant women.
- Interventions to prevent smoking uptake and maximise cessation should be implemented at every level of the health care system.
- Doctors and public health officials should encourage smoke-free environments, including smoke-free homes.

Second-hand smoke exposure is also an important cause of respiratory symptoms and increased risk for COPD, especially in partners and offspring of smokers.^{85 (Level I)} Long-term indoor exposure, combined with crowded living conditions in poorly ventilated homes, adds to the total burden of particulate exposure and increases the risk of developing COPD.^{86 (Level I)} Adults should not smoke in the immediate vicinity of non-smokers, especially children, nor in enclosed spaces such as cars and poorly ventilated rooms that expose others to increased risk. Children less than two years old who are passively exposed to cigarette smoke have an increased prevalence of respiratory infections, and are at a greater risk of developing chronic respiratory symptoms later in life.^{87,88 (Level I)}

5.3 Smoking Cessation

Quitting smoking can prevent or delay the development of airflow limitation, or reduce its progression,^{88 (Level I)} and can have a substantial effect on subsequent mortality.^{89 (Level I)} All smokers – including those who may be at risk for COPD as well as those who already have the disease – should be offered the most intensive smoking cessation intervention available.

Smoking cessation interventions are effective in both sexes, in all racial and ethnic groups, and in pregnant women. Age influences quit rates, with young people less likely to quit. Nevertheless, smoking cessation programmes can be effective in all age groups. Effective interventions include individual as well as group programmes such as community-based stop-smoking challenges. The essential approaches are:

1. Pharmacotherapy

- Nicotine replacement therapy (NRT) in the form of transdermal patches, gums, lozenges and nasal sprays
- Varenicline
- Bupropion
- Nortriptyline

2. Counselling from doctors and other health professionals, given either by individual face-to-face interactions, group interactions or through telephone or web-based quit smoking services

3. Combination of counselling and pharmacotherapy

A successful smoking cessation strategy requires a multi-faceted approach that includes sustained escalation in tobacco taxation, coherent government policies and legislations to reduce tobacco demands and production as well as health education and frequent dissemination of consistent anti-tobacco messages through the media and settings such as schools.^{90,91 (Level III)} However, healthcare providers, including doctors, nurses, dentists, psychologists, pharmacists and others, are key to the delivery of smoking cessation messages and interventions. Healthcare workers should encourage all patients who smoke to quit, even those patients who attend for unrelated reasons and do not have symptoms of COPD.^{92 (Level III)}

5.4 Five Step Programme for Intervention (5A)^{91 (Level III)}

- 1. ASK:** Systematically identify all tobacco users at every visit.
Implement an office-wide system that ensures that, for EVERY patient at EVERY clinic visit, tobacco-use status is queried and documented.
- 2. ADVISE:** Strongly urge all tobacco users to quit in a clear, strong, and personalised manner.
- 3. ASSESS:** Determine willingness to make a quit attempt.
Ask every tobacco user if he or she is willing to make a quit attempt at this time (e.g., within the next 30 days).
- 4. ASSIST:** Aid the patient in quitting.
 - a. Help the patient with a quit plan
 - b. Provide practical counselling
 - c. Provide intra-treatment social support
 - d. Help the patient obtain extra-treatment social support
 - e. Recommend use of approved pharmacotherapy except in special circumstances
 - f. Provide supplementary materials.
- 5. ARRANGE:** Schedule follow-up contact, either in person or via telephone.

5.5 Counselling

Counselling delivered by doctors and other healthcare professionals significantly increases quit rates over self-initiated strategies.^{93 (Level I)} Even a brief (three-minute) period of counselling to urge a smoker to quit results in smoking cessation rates of 5-10%.^{94 (Level II-2)} At the very least, this should be done for every smoker at every healthcare provider visit.^{95 (Level III)}

5.6 Pharmacotherapy

Numerous effective pharmacotherapies for smoking cessation now exist,^{96 (Level III)} and pharmacotherapy is recommended when counselling is not sufficient to help patients quit smoking. Special consideration should be given before using pharmacotherapy in selected populations:

- People with medical contraindications
- Light smokers (fewer than 10 cigarettes/day)
- Smokers who are pregnant
- Adolescent smokers.

All forms of nicotine replacement therapy are significantly more effective than placebo.^{96 (Level III)} Every effort should be made to tailor the choice of replacement therapy to the individual's culture and lifestyle to improve adherence. Other pharmacotherapy, like bupropion^{97 (Level I)} and nortriptyline have also been shown to increase long term quit rates,^{98,99 (Level I)} but should always be used as one element in a supportive intervention programme rather than on their own. Varenicline, a nicotinic acetylcholine receptor partial agonist that aids smoking cessation by relieving nicotine withdrawal symptoms and reducing the rewarding properties of nicotine has been demonstrated to be safe and efficacious.^{100 (Level I)} The main adverse effect of varenicline is nausea, mostly mild or moderate which usually subsides over time. There are recent concerns that varenicline may be linked with depressed mood, agitation or suicidal thinking and behaviour in some smokers.^{101 (Level III)}

5.7 Occupational Exposure

Many occupations have been shown to be associated with increased risk of developing COPD, particularly those that involve exposure to fumes and mineral and biological dusts. Although it is not known how many individuals are at risk of developing respiratory disease from occupational exposures, many occupationally induced respiratory disorders can be reduced or controlled through a variety of strategies aimed at reducing the burden of inhaled particles and gases.^{102 (Level II-2),103,104 (Level III)}

The main emphasis should be on primary prevention, which is best achieved by the elimination or reduction of exposures to various substances in the workplace. Secondary prevention, achieved through surveillance and early case detection, is also of great importance. Both approaches are necessary to improve the present situation and to reduce the burden of lung disease.

5.8 Indoor and Outdoor Air Pollution

Individuals experience diverse indoor and outdoor environments throughout the day, each of which has its own unique set of air contaminants and particulates that cause adverse effects on lung function.^{104 (Level III)}

Reducing the risk from indoor and outdoor air pollution is feasible and requires a combination of public policy and protective steps taken by individual patients. Reduction of exposure to smoke from biomass fuel, particularly among women and children, is a crucial goal to reduce the prevalence of COPD.

5.9 Steps for Health Care Providers/Patients

The health care provider should consider COPD risk factors including smoking history, family history, exposure to indoor/outdoor pollution and socioeconomic status for each individual patient. Some steps to consider are:

- Individuals at risk for COPD should be counselled concerning the nature and degree of their risk for COPD
- If various solid fuels are used for cooking and heating, adequate ventilation should be encouraged
- Respiratory protective equipment has been developed for use in the workplace in order to minimise exposure to toxic gases and particles
- Ventilation and interventions to meet safe air quality standards in the workplace offer the greatest opportunity to reduce worker exposure to known atmospheric pollutants and reduce the risk of developing COPD.

In patients who have been diagnosed with COPD:

- Persons with advanced COPD should monitor public announcements of air quality and be aware that staying indoors when air quality is poor may help reduce their symptoms.
- The use of medication should follow the usual clinical indications; therapeutic regimens should not be adjusted because of the occurrence of a pollution episode without evidence of worsening of symptoms or lung function.

Recommendation: Smoking Cessation
1. Smoking cessation is the single most effective and cost effective intervention in most people to reduce the risk of developing COPD and stop its progression. All smokers should be offered smoking cessation interventions. <i>[Grade A]</i>

SECTION 6 MANAGING STABLE COPD

6.1 The Objectives of Managing Stable COPD

These include:

1. Preventing disease progression
2. Reducing frequency and severity of exacerbation
3. Improving exercise tolerance
4. Improving lung function and general health
5. Improving patient's symptoms, e.g. dyspnoea, cough and tiredness.
6. Improving quality of life
7. Reducing mortality.

6.2 Patient Education

Patient education, essential in any chronic illness, should be individualised to address the cause, disease severity, specific symptoms, response to therapy and other co-morbidities. It is aimed to improve their quality of life.

Topics for patient education may include:

- A brief explanation on
 - o The aetiologies of COPD which will enable patients to take necessary steps toward avoiding these risk factors
 - o The pathophysiological changes of COPD which have contributed to their symptoms
 - o The differences between asthma and COPD (**refer to Table 4-2**).
- Information about the natural course of the illness:
 - o COPD is a progressive disease
 - o Smoking cessation has the most significant effect on modifying the course of disease progression
 - o COPD exacerbation accelerates disease progression. Education has been shown to improve health outcomes in patients with chronic illnesses.^{106 (Level I),107 (Level III)}
- Patients should be counselled on their roles in optimising treatment and health outcomes. Studies have shown that education plays a role in improving patients' skills, ability to cope with illness and health status.^{108,109 (Level III), 110 (Level II-1), 111 (Level I)}
- Instruction on how to use an inhaler, assessing inhaler technique (consider recommending a holding-chamber if technique is unsatisfactory) and other treatment.
- Self-management plan in acute situation (e.g., recognition of a COPD exacerbation, treatment intervention; and, when to seek medical help).
- Strategies on minimising dyspnoea.
- Information on proper nutrition intake, exercise and pulmonary rehabilitation.
- Roles of vaccination.
- For patients with more severe disease, counselling may include:
 - o Information about complications of COPD
 - o information about long-term oxygen therapy
 - o Advanced directive and end-of-life decisions. Prospective end-of-life discussion can lead to better understanding of advanced directives and effective therapeutic decision at end of life.^{112 (Level II-1)}

Limited published data suggest that the chronic care model in COPD management results in lower rates of hospitalisations and emergency/unscheduled visits and shorter lengths of hospital stay.^{113 (Level I)} However, COPD patients recruited to a comprehensive COPD education programme in Canada had significantly fewer exacerbations and hospitalisations.^{114 (Level I)} They also utilised less health care resources. These results may encourage adoption of similar programmes locally.

6.3 Influenza Vaccination

- Reduces the risk of COPD exacerbation.^{115 (Level II-2)}
- COPD patients with influenza have a significant risk of requiring hospitalisation.^{116 (Level II-1)}
- Annual influenza vaccination reduces influenza-related acute respiratory illness by 76%.^{117 (Level I)}
- In a retrospective, multi-season cohort study, elderly patients (aged ≥ 65 years-old) with chronic lung diseases (some COPD patients were included) who were vaccinated with the influenza vaccine showed a 52% reduction of hospitalisation (secondary to influenza and pneumonia) and a 70% reduction in the risk of death compared to unvaccinated patients.^{116 (Level II-1)}

6.4 Pneumococcal Vaccination

- The benefit of pneumococcal vaccination in COPD is less well established. Some reports state that the vaccine has up to a 65% efficacy in COPD patients,^{118 (Level II-2)} although an effect on reducing the frequency of COPD exacerbation has yet to be established.
- A recent report demonstrated a reduction in the prevalence of community-acquired pneumonia following pneumococcal vaccination in a subgroup of COPD patients younger than 65 years with an $FEV_1 < 40\%$ predicted.^{119 (Level I)}
- Hence, a 23-valent polysaccharide vaccine (PPV23) is recommended for patients who are younger than 65 years but with a $FEV_1 < 40\%$ predicted (irrespective of age)
- Even though the vaccination of PPV23 remains controversial, the panels support the WHO position stand to vaccinate all COPD patients at least once in their lifetime and have it repeated ≥ 5 years (with a maximum of two doses in one's lifetime).^{120 (Level III)}

6.5 Treatment Strategy: Consisting of Pharmacological & Non-pharmacological Interventions

6.5.1 Pharmacological Therapy

- Bronchodilators remain the mainstay of pharmacological therapy.
 - o They reduce airway smooth muscle tone, improve expiratory flow rate, reduce air-trapping and hyperinflation of the lung.
 - o They also improve the patients' dyspnoea scores, increase exercise tolerance, reduce disability in daily living and improve overall health status.
 - o Optimal pharmacotherapy should be guided by the patients' symptoms, level of activity and frequency of COPD exacerbation.

Inhaled short-acting bronchodilators

- These include inhaled short-acting β_2 -agonists (SABAs) and inhaled short-acting anticholinergics (SAACs).

Inhaled SABAs

(Examples: MDI salbutamol 200 µg, fenoterol 200 µg or terbutaline 500 µg PRN or 4 to 6 hourly)

- They have been shown to improve lung function, dyspnoea and exercise tolerance.
 - A systematic review of 13 randomised controlled trials (RCTs) showed that inhaling SABAs on a regular basis for at least 7 days in patients at various stages of COPD (FEV₁ of < 70% predicted) is associated with improvements in post-bronchodilator lung function and a decrease in both breathlessness and treatment failure. Nonetheless, they have not been shown to have a consistent impact on quality of life.^{121 (Level I)}

Inhaled SAACs

(Example: MDI ipratropium bromide 40 µg 6 hourly)

- Inhaled SAACs act on the muscarinic receptors by blocking their bronchoconstrictor effects and reducing mucus secretions. An increase in FEV₁ was observed with anticholinergics compared to the placebo.^{122-125 (Level I)} Some studies also found that the inhalation of SAACs is associated with an improvement in dyspnoea, a reduction in the need for rescue medications,^{123-126 (Level I)} and an improvement in the quality of life.^{125 (Level I)} The combination of inhaled SABA and SAAC achieves a greater bronchodilator effect than either one alone.^{123,127 (Level I)} However, there was no data to show that either SAAC or SABA reduces exacerbation.

Inhaled long-acting bronchodilators

- Consist of long-acting β₂-agonists (LABAs) and long-acting anticholinergics (LAACs)
- Offer a more sustained relief of symptoms and improvement of lung function
- Also improve patients' compliance to treatment.

Inhaled LABA

(Examples: salmeterol 50 µg twice daily or formoterol 9 µg twice daily)

- The duration of action of LABAs is 12 hours or longer as compared to 4 hours in SABAs.
- A review of 23 randomised controlled trials showed that the treatment of patients with COPD (FEV₁ < 75% predicted) using LABA as compared to placebo produces modest increases in lung function, and improves health-related quality of life and symptoms.^{127 (Level I)} In this review, LABA was also associated with a significant reduction in COPD exacerbations.^{127 (Level I)}
- The results of this systematic review were further supported by the TORCH study, a 3-year randomised controlled study, which showed that salmeterol significantly reduced exacerbations, improved lung function and improved health-related quality of life as compared with placebo in patients with COPD of FEV₁ < 60% predicted.^{128 (Level I)}

Inhaled LAAC

- Tiotropium is the only LAAC currently in the market. The dose is 18 µg once daily administered through a Handihaler[®].
- It is effective for at least 24 hours in patients with airflow limitation and dynamic hyperinflation.
- Several clinical trials using tiotropium for 6 weeks to 12 months showed improvement in exercise tolerance, quality of life and dyspnoea as well as reduction in exacerbation as compared to the placebo.^{129-132 (Level I)}
- This is further supported by a 4-year prospective study, the UPLIFT trial, which demonstrated that the use of tiotropium in patients with FEV₁ < 70% predicted, was associated with a

reduction in exacerbation and hospitalisation due to exacerbation but was not associated with a reduction in the rate of decline in FEV₁ when compared to placebo.^{133 (Level I)}

- A few studies have suggested that tiotropium produces superior bronchodilation as compared to the LABAs.^{134,135 (Level I)}

Inhaled LAAC and inhaled LABA

Two small short-term studies showed that the combination of tiotropium and formoterol may have an additive effect on lung function and may reduce the use of rescue medication.^{135,136 (Level I)} However, in a larger and longer study on patients with moderate to severe COPD, the OPTIMAL study, the addition of salmeterol to tiotropium did not show any improvement in lung function or a reduction in exacerbation compared to tiotropium alone.^{137 (Level I)} Nonetheless, this combination did improve the health-related quality of life.

Inhaled LABA and inhaled corticosteroid (ICS) combination

The combination of LABA/ICS has been shown to improve lung function, quality of life and reduce exacerbations compared with placebo in COPD patients with FEV₁ < 65% predicted.^{128, 138-140 (Level I)} In the TORCH study, there was a trend towards a reduction in mortality in patients taking LABA/ICS compared to placebo, though the reduction was not statistically significant.^{128 (Level I)} In the same study, the decline in lung function in the patients taking LABA/ICS (39 mL/year) was also slower compared with placebo (55 mL/year).^{141 (Level II-1)} When ICS/LABA was compared with LAAC in the INSPIRE study among patients with severe and very severe COPD with a history of exacerbation, there was no difference in exacerbation rate but the former was associated with better health related quality of life and lower mortality.^{142 (Level I)} However, this study was not statistically powered to study the mortality outcome.

Inhaled LAAC and inhaled LABA/ICS combination

In the UPLIFT study, where 53% of the study patients had severe to very severe COPD and 46% of them were on ICS/LABA, the addition of tiotropium was associated with a significant improvement in lung function, a significant delay in time to first exacerbation, significant reduction in number of exacerbations and significant improvement in health-related quality of life.^{133 (Level I)} Thus, in patients who are already on a LABA/ICS combination, but still have persistent symptoms, addition of a LAAC should be considered. On the other hand, the OPTIMAL study showed that adding ICS/LABA to tiotropium significantly improved lung function, improved quality of life and reduced hospitalisation but did not reduce exacerbation rates.^{137 (Level I)}

Inhaled corticosteroids (ICS)

(Examples: fluticasone 500 µg twice daily by Accuhaler®, budesonide 400 µg twice daily by Turbuhaler®)

- The trial outcomes using ICS on COPD are rather conflicting. The EUROSCOP trial^{143 (Level I)} and the Copenhagen Lung Health Study^{144 (Level I)} showed the use of ICS in mild COPD does not slow the rate of decline of FEV₁. However, the ISOLDE trial^{145 (Level I)} and the study by Paggiaro PL et al^{146 (Level I)} showed that treatment with high dose ICS, in this case, fluticasone 1000 µg a day, in moderate to severe COPD decreases exacerbations and modestly slows the progression of respiratory symptoms, but has minimal or no impact on lung function. Two recent multi-centre randomised controlled studies confirmed that ICS alone improves FEV₁ and health-related quality of life, and reduces moderate to severe exacerbations.^{128,140 (Level I)} Furthermore, the TORCH study showed a slower rate of decline in lung function in patients taking high dose ICS alone (42 mL/year) as compared with placebo (55 mL/year).^{141 (Level II-1)}

Oral corticosteroids

- About 10% of COPD patients show significant improvement in lung function (defined as an improvement of at least 20% of FEV₁) after oral corticosteroid administration.^{147 (Level I)}
- However, chronic systemic corticosteroid usage is known to be associated with potentially serious side-effects such as osteoporosis, premature cataract, muscle weakness, diabetes mellitus and hypertension.
- Indeed, one study showed that in severe COPD patients, maintenance treatment with oral glucocorticoids is associated with increased mortality in a dose-dependent manner.^{148 (Level II-2)}
Hence, prolonged courses of systemic corticosteroids for the treatment of COPD should be discouraged.^{148 (Level II-2)}

Combination of LAAC and ICS

There is no data to support the use of this combination.

Methylxanthines

(Example: oral sustained-release theophylline 125-300 mg twice daily)

- Theophylline is a weak bronchodilator, hence offering only a modest improvement in symptoms and exercise tolerance.
- This drug should be relegated to third line therapy. It should only be added if inhaled long-acting bronchodilators and ICS do not achieve the desirable control of symptoms.
- It may be added to bronchodilator treatment if patients still have persistent symptoms despite LABA.^{149 (Level II-1)}
- This potential benefit should be weighed against its side-effects, such as nausea, abdominal discomfort, diarrhoea and risk of cardiac arrhythmias.
- In view of the narrow therapeutic window and significant toxicity, monitoring of drug levels is desirable. The therapeutic range is 10-20 mg/L.^{150 (Level III)}
- Some recent studies suggest that it has an anti-inflammatory effect.^{151,152 (Level I)} In one study, COPD patients treated with low doses of theophylline (with concentration < 10 mg/L) were noted to have reduced neutrophil counts, interleukin (IL)-8 concentration and myeloperoxidase levels, as well as reduced neutrophil chemotactic responses in induced sputum.^{151 (Level I)} In another placebo-controlled study, a significant reduction in myeloperoxidase and neutrophil elastase was noted after four weeks of treatment with theophylline.^{152 (Level I)}
- Corticosteroids suppress the inflammatory genes through deacetylation of core histone by histone deacetylase (HDAC). It has been found that HDAC activity is reduced in cells of cigarette smokers possibly due to increased oxidative stress.^{153,154 (Level II-1)} There is some evidence to suggest that low doses of theophylline restore steroid responsiveness in COPD patients by increasing the HDAC activity.^{155 (Level II-1)}

Phosphodiesterase-4 (PDE4) inhibitors


(e.g. oral roflumilast 500 mg once daily, cilomilast 15 mg twice daily)

- Recently, treatment with PDE4 inhibitors have been studied in COPD patients.
- The results of four phase III clinical studies have been recently published on roflumilast. Two 12-month studies of patients with severe COPD and bronchitic symptoms demonstrated that roflumilast produced a statistically significant and clinically relevant reduction in exacerbations, 17% per patient per year (rate of 1.14 events per year with roflumilast vs. 1.37 per year with placebo, $p < 0.001$).^{156 (Level I)} This reduction in exacerbations occurred even in patients treated with concomitant LABA. The other two studies involving patients with moderate-to-severe COPD showed roflumilast improved patients' pre-bronchodilator FEV₁ beyond long-acting bronchodilators (salmeterol or tiotropium). However, in the latter study, it did not lead to a statistically significant reduction in COPD exacerbations.^{157 (Level I)} Across the studies, roflumilast demonstrated a statistically significant improvement in pre-bronchodilator FEV₁, in the range of 48 to 80 mL.
- One 24-week, randomised, placebo-controlled study of COPD patients treated with cilomilast showed quite similar results. A difference of 40 mL of pre-bronchodilator FEV₁ was detected, favouring cilomilast. There was a clinically significant mean reduction by 4.1 in the total St George's Respiratory Questionnaire score in subjects receiving cilomilast therapy compared with those on placebo. A higher proportion of subjects in the cilomilast group were exacerbation-free at 24 weeks compared with those on placebo (74% versus 62%).^{158 (Level I)}
- Significant adverse effects in subjects treated with PDE4 inhibitors include nausea, diarrhoea, weight loss and headache.
- PDE4 inhibitors maybe an important treatment for patients with COPD, particularly those with bronchitic symptoms, in the future.

Recommendations: Managing Stable COPD

1. Treatment recommendation should be based on disease severity, symptoms and frequency of COPD exacerbations (**Figure 6.1**). [Grade C]
2. COPD patients at any stage of disease severity should be advised to quit smoking if they still smoke. [Grade A]
3. In patients with mild COPD who are symptomatic, SABA or SAAC or a combination of both may be prescribed. [Grade C]
4. In patients with moderate to very severe COPD with persistent symptoms, but without frequent COPD exacerbations, either a LAAC or LABA may be initiated. If symptoms persist despite this treatment, an ICS/LABA combination should be added; and vice versa. [Grade A]
5. Theophylline can be added to patients who are symptomatic despite maximum inhaled therapy. [Grade C]
6. In resource-limited settings, alternative treatment may be used (**Figure 6.2**). [Grade C]

Figure 6-1: Algorithm for Managing Stable COPD




Notes:

- SABA – Short-acting β_2 agonist; SAAC – Short-acting anticholinergic; LAAC – Long-acting anticholinergic; LABA – Long-acting β_2 agonist; ICS – Inhaled corticosteroid; LVRS – lung volume reduction surgery
- ICS dose per day should be at least 500 μg of fluticasone or 800 μg of budesonide

- All COPD patients, irrespective of disease severity, should be prescribed SABA or SABA/SAAC combination (Berodual®/Combivent®) as needed. SABA has a more rapid onset of bronchodilatation than SAAC.
- Defined as need for rescue bronchodilators more than twice a week.
- Frequent exacerbation is defined as one or more episodes of COPD exacerbation requiring systemic corticosteroids ± antibiotics and/or hospitalisation over the past one year
- Consider alternative causes - it is less common for patients with mild COPD to have frequent exacerbations; similarly, respiratory failure is uncommon in patients with mild to moderate COPD severity. Hence, in such patients, an alternative cause should be explored even if the COPD diagnosis is firmly established.

Figure 6-2: Algorithm for Managing Stable COPD in Resource-Limited Settings



Notes:

1. SABA – Short-acting β_2 agonist; SAAC – Short-acting anticholinergic; LAAC – Long-acting anticholinergic; LABA – Long-acting β_2 agonist; ICS – Inhaled corticosteroid; LVRS – lung volume reduction surgery
2. ICS dose per day should be at least 500 μg of fluticasone or 800 μg of budesonide
- a. All COPD patients, irrespective of disease severity, should be prescribed SABA or SABA/SAAC combination (Berodual[®]/Combivent[®]) as needed. SABA has a more rapid onset of bronchodilatation than SAAC.
- b. Defined as need for rescue bronchodilators more than twice a week.
- c. Frequent exacerbation is defined as one or more episodes of COPD exacerbation requiring systemic corticosteroids \pm antibiotics and/or hospitalisation over the past one year
- d. Consider alternative causes - it is less common for patients with mild COPD to have frequent exacerbations; similarly, respiratory failure is uncommon in patients with mild to moderate COPD severity. Hence, in such patients, an alternative cause should be explored even if the COPD diagnosis is firmly established.

SECTION 7 MANAGING STABLE COPD: NON-PHARMACOLOGICAL TREATMENTS

7.1 Pulmonary Rehabilitation in COPD

Pulmonary rehabilitation aims to reduce symptoms, decrease disability, increase participation in physical and social activities, and improve the overall quality of life (QoL) for patients with chronic respiratory diseases. It includes exercise, education, psychosocial and behavioural intervention by an interdisciplinary team of specialists.^{159 (Level III)}

Most structured pulmonary rehabilitation programmes last between 6 and 12 weeks.^{160,161 (Level III)} They have been demonstrated to produce benefits that last between 12 and 18 months. There is no consensus on the optimal duration of pulmonary rehabilitation programmes. An exercise programme can be helpful in the home^{162-164 (Level I); 165,166 (Level II-1)}, in the hospital^{167 (Level II-1)} or in community settings.^{168 (Level I)} In Malaysia, only a small fraction of patients with COPD are able to get exercise training as only a few hospitals have programmes that provide closely supervised exercise training and access to these programs is limited.

General aerobic conditioning is more helpful than specific training of respiratory muscles.^{160,161 (Level III),169 (Level I)} The muscles of ambulation should be a focus of pulmonary rehabilitation, emphasising endurance and strength training. Benefit is seen even in irreversible pulmonary disorders, since much of the disability and handicap results not just from the respiratory disorder per se but from secondary morbidities that often are treatable. Although the degree of airway obstruction or lung hyperinflation does not change much with pulmonary rehabilitation, reversal of muscle deconditioning and better pacing enables patients to walk further with less dyspnoea. Supplemental oxygen should be used during rehabilitative exercise training in patients with severe exercise-induced hypoxaemia.^{161 (Level III)}

Benefits of pulmonary rehabilitation include ^{160,161 (Level III),170,171 (Level I)}:

- Improvement in exercise tolerance
- Reduction in the sensation of dyspnoea
- Improvement in health-related quality of life (HRQoL)
- Improvement in peripheral muscle strength and mass
- Reduction in number of days spent in hospital
- Cost effectiveness
- Improvement in the ability to perform routine activities of daily living
- Reduction in exacerbations
- Reduction in anxiety and depression.

Improvements in exercise tolerance are maintained for 6 to 12 months. Improvements in HRQoL may be maintained for longer periods.

There is insufficient evidence to determine if pulmonary rehabilitation improves survival among patients with COPD.^{159,161 (Level III)}

Recommendations: Pulmonary Rehabilitation

1. Pulmonary rehabilitation should be considered as an addition to medications for symptomatic patients who have Stage II, III, or IV COPD. *[Grade A]*
2. Efforts should be directed towards the setting up of both hospital and home-based programmes locally. *[Grade A]*

7.2 Domiciliary Oxygen Therapy for COPD

Long-term administration of oxygen of > 15 hours per day to patients with chronic respiratory failure has been shown to increase survival.^{172,173 (Level I)} Home oxygen therapy does not appear to improve survival in patients with mild to moderate hypoxaemia or in those with only oxygen desaturation at night.^{174 (Level I)} The goal of long-term oxygen therapy (LTOT) is to increase the baseline PaO₂ to at least 60 mmHg (or 8.0 kPa) at rest, and/or produce an SaO₂ of at least 90%.

Indications for LTOT^{69 (Level III)} :

- PaO₂ ≤ 7.3 kPa (55 mmHg) or SaO₂ ≤ 88%, with or without hypercapnia; or
- PaO₂ between 7.3 and 8.0 kPa (55–60 mmHg) or SaO₂ of 89%, if there is evidence of pulmonary hypertension, peripheral oedema suggesting congestive heart failure, or polycythaemia (haematocrit > 55%).

Assessment for LTOT should not be done during an exacerbation or during the recovery period of an exacerbation. Arterial blood gas measurements should be made on two occasions when the patient is in a stable condition and on optimal treatment.^{69 (Level III)}

Oxygen therapy is not indicated for patients:

- with severe airflow limitation whose main complaint is dyspnoea but who maintain a PaO₂ > 8 kPa (60 mmHg) and who show no secondary effects of chronic hypoxia
- who continue to smoke cigarettes
- who have not received adequate therapy of other kinds (eg, inhaled and oral bronchodilators and corticosteroids, treatment for right ventricular failure or for any respiratory infection)
- who are not sufficiently motivated to undertake the discipline required for oxygen therapy.

Domiciliary oxygen therapy is available in Malaysia from a variety of providers. Oxygen concentrators are generally regarded more cost-effective. It should be prescribed by a qualified medical practitioner and titrated carefully due to concerns of carbon dioxide retention. Patients should be reassessed 1–2 months after starting continuous or nocturnal oxygen therapy, both clinically and by measurement of PaO₂ and PaCO₂.^{175 (Level I)} Subsequent review should be undertaken at least annually, or more often, according to the clinical situation.

Recommendations: Long-term Oxygen Therapy (LTOT)

1. LTOT should be prescribed for all patients with COPD who have chronic hypoxaemia. *[Grade A]*
2. An oxygen concentrator is the most cost-effective method for delivering LTOT. *[Grade A]*

7.3 Nutrition in COPD

Cachexia is an important systemic manifestation in COPD.^{176 (Level III), 177 (Level II-2)} Weight loss is a marker of disease severity in advanced COPD and it is associated with adverse outcomes independent of lung function. Low BMI is associated with higher mortality. Weight loss may further exacerbate decreased respiratory muscle strength and increase dyspnoea and impair immunity.^{178 (Level II-2), 179 (Level I)} The general assessment of patients with COPD should include weight and the calculation of BMI at each visit. The goal is to try to maintain a reasonable body weight and BMI (between 22 and 27 kg/m²) and keep serum albumin levels above 35 g/L.^{179 (Level I)} A balanced diet with adequate caloric intake in conjunction with exercise to prevent or reverse malnutrition and muscle atrophy is prudent.^{180 (Level III)} However, excessive weight gain should be avoided, and obese patients should strive to gradually reduce body fat. Studies of nutritional supplementation alone have not shown improvement in pulmonary function or exercise capacity. Trials of anabolic steroids, growth hormone supplementation, and tumour necrosis factor- α (TNF- α) antagonists in reversing malnutrition and improving functional status and prognosis in COPD have been disappointing.^{179 (Level I), 180 (Level III)}

The role of pulmonary rehabilitation is now well-recognised in COPD. Ongoing research is currently exploring how nutritional support can enhance exercise training and optimise the effects of pulmonary rehabilitation.^{181 (Level III)}

Recommendation: Nutrition in COPD

1. A balanced diet with adequate caloric intake in conjunction with exercise is recommended in patients with COPD. [Grade B]

7.4 Lung Volume Reduction for COPD

7.4.1 Lung Volume Reduction Surgery (LVRS)

Lung volume reduction by resection of non-functioning emphysematous areas improves exercise tolerance and decreases 2-year mortality in patients with severe, predominantly upper-lung emphysema who have low baseline exercise capacity after pulmonary rehabilitation.^{182,183 (Level I)}

7.4.2 Bullectomy

Bullectomy has been reported to improve lung function and dyspnoea in selected patients by removal of large bullae compressing on adjacent lung parenchyma.^{184 (Level III)} HRQoL was maintained three years post-bullectomy. Surgical techniques used have included thoracotomy, video-assisted thoracoscopy and stapled wedge resection.

7.4.3 Minimally-Invasive Lung Volume Reduction Procedures

Newer minimally-invasive techniques of lung volume reduction such as endoscopic bronchial valve placement await the results of large scale randomised studies.^{185,186 (Level III)}

7.5 Lung Transplantation

Lung transplantation is available in Malaysia. However, at the present time it is limited to younger patients with other chronic lung diseases. Patients with COPD are considered for lung transplantation when^{187 (Level III)}:

- life expectancy is not predicted to exceed 24-36 months despite optimal and maximal medical management
- they have class III or IV New York Heart Association (NYHA) symptoms.
- < 60 years old with an FEV₁ < 25% predicted after bronchodilator therapy or with severe pulmonary hypertension.

The 5-year survival after transplantation for emphysema is 45 to 60% in Western series.^{188,189 (Level III)} Lifelong immunosuppressive therapy is required.

Recommendation: Surgical Treatment for COPD

1. COPD patients who continue to deteriorate despite optimal medical therapy may be considered for surgical treatment. [Grade A]

7.6 COPD and Surgery

A careful evaluation of patients with COPD undergoing surgery should include identification of high-risk patients and aggressive treatment. Elective surgery should be deferred in patients who are symptomatic, have poor exercise capacity or have acute exacerbations.

Patients with COPD are several times more likely to have a major postoperative complication.^{190,191 (Level II-2), 192 (Level I), 193 (Level II-2)} Similarly, an FEV₁ < 60% predicted was found to be an independent predictor of increased mortality in patients undergoing coronary artery bypass graft procedures.^{194 (Level III)} In general, the incidence of postoperative pulmonary complications is inversely related to the distance of the surgical incision from the diaphragm.^{194 (Level III)}

The risk of respiratory failure is increased in patients undergoing pneumonectomy with a preoperative FEV₁ of < 2 L or < 50% predicted and/or diffusing capacity of the lungs (DL_{CO}) < 50% predicted.^{195 (Level III)} High risk patients should undergo further testing such as lung perfusion and exercise capacity tests.^{195 (Level III)} Benefits of surgery must be weighed against known risks.

Patients with COPD should be treated aggressively to achieve the best possible baseline function. Bronchodilators, smoking cessation (at least 4-8 weeks preoperatively is optimal), antibiotics, and chest physical therapy may help significantly reduce pulmonary complications.^{195-197 (Level III)} The role of pre-operative steroids is uncertain although smaller studies have indicated reduction of postoperative pulmonary and non-pulmonary complications in COPD patients undergoing coronary artery bypass surgery.^{198 (Level II-1), 199 (Level II-2)} Consider postponing elective surgery if improvement of pulmonary function is possible and requires more time. The patient should be educated regarding early postoperative deep breathing and incentive spirometry.

Regional anaesthesia and laparoscopic techniques and limited duration of surgery should be considered where feasible.^{200,201 (Level III)} Careful and vigilant use of muscle relaxants is advisable to avoid postoperative muscle weakness. Adequate hydration should be maintained to allow mobilisation of airway secretions. Postoperatively, early ambulation should be encouraged and the use of opioids that may depress ventilation should be minimised.

Listed in the following recommendation box are measures to minimise pulmonary complications in at-risk patients. ^{201 (Level III), 202 (Level I), 203 (Level III)}

Recommendations: Surgery in COPD Patients

The following measures help minimise pulmonary complications in at-risk patients:

Preoperative

- Smoking cessation
- Antibiotics for acute bronchitis
- Optimise COPD treatment regimens
- Educate patient on lung expansion manoeuvres
- Consider inspiratory muscle training or pulmonary rehabilitation in high-risk patients.

Postoperative

- Early mobilisation
- Lung expansion manoeuvres
 - consider continuous positive airway pressure (CPAP) in high-risk patients
- Adequate pain control
 - consider epidural analgesia in at-risk patients
 - avoid opiates
- Selective use of nasogastric decompression and total parenteral nutrition
- Deep vein thrombosis prophylaxis.

[Grade B]

SECTION 8 MANAGING EXACERBATIONS OF COPD

8.1 Introduction

The natural course of COPD is of gradual decline in lung function with episodes of exacerbations.

8.2 Definition of Acute Exacerbation of COPD

Exacerbation is defined as an event in the natural course of the disease characterised by a sustained (lasting 48 hours or more) worsening of the patient's baseline dyspnoea, cough, and/or sputum that is beyond normal day-to-day variations, is acute in onset, and may warrant a change in regular medication.^{69,204 (Level III)}

8.3 Morbidity and Mortality Associated with Acute Exacerbations of COPD

Acute exacerbation of COPD (AECOPD) is a major cause of morbidity and mortality^{205 (Level III)} and incurs huge cost in terms of healthcare resource utilisation.^{206 (Level II-2)} Exacerbations impact negatively on lung function^{207 (Level II-2)} and HRQoL.^{208 (Level III)} The impact is significant and patients may take a long time to recover.^{209 (Level II-2)} Some patients never recover fully and have repeated exacerbations.^{209 (Level II-2)}

Measures to prevent AECOPD are important to reduce morbidity and mortality. AECOPD should be suspected if smokers present with symptoms of chest infection.

8.4 Causes of Acute Exacerbations of COPD

Exacerbations are associated with an increase in airway inflammation and are caused mainly by lower respiratory tract infections and inhalation of pollutants. Cigarette smoking is a major cause of COPD and smoking cessation is effective in reducing risk of exacerbation^{210 (Level II-2)} and risk of hospitalisation.^{211 (Level II-2)} Most (50 to 60%) exacerbations are caused by bacterial or viral respiratory infections,^{212 (Level III), 213 (Level II-2)} while 10 to 20% are due to environmental factors^{214 (Level II-2)} and non-compliance to medications, and 30% are of unknown aetiology.^{215-217 (Level III)} Bacterial organisms that have been isolated in various studies of AECOPD include *Haemophilus influenzae*, *Moraxella catarrhalis*, *Streptococcus pneumoniae*, *Mycoplasma pneumoniae*, *Chlamydomphila pneumoniae*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Acinetobacter baumannii* and *Staphylococcus aureus*.^{217 (Level III), 218, 219 (Level II-3)} Other precipitating factors include congestive heart failure, cold air and pulmonary embolism.^{204 (Level III), 220 (Level II-2)}

8.5 Diagnosis and Assessment of Severity

Exacerbation of COPD is a clinical diagnosis which is supported by physical examination and investigations. Usual symptoms are increased dyspnoea, cough and production of sputum which may become purulent. Non-specific symptoms such as lethargy, insomnia, sleepiness, depression and confusion may be present. Patients tend to underestimate their symptoms and underreport exacerbations^{221 (Level III)} probably because they have poor understanding of their disease and the term "exacerbation".^{208 (Level III)}

Assessment of severity is based on history, physical examination and investigation findings.

8.5.1 History and Physical Examination

It is important to ascertain the patient's baseline condition before the exacerbation, the development of any new symptoms, the severity of COPD, the presence of co-morbidities, as well as previous and current medications. Severity of COPD should be assessed based on FEV₁, previous exacerbations, hospital admissions especially history of admission into the intensive care unit (ICU) and receiving invasive or non-invasive ventilation and the presence of complications of COPD. The history may also help reveal possible cause(s) of and precipitating factors for the exacerbation and concomitant medical illnesses. It is worth noting that anxiety and depression are common in COPD patients and in those with exacerbations.^{222 (Level II-2), 223 (Level III)} History can also help rule out other differential diagnoses (see **8.6**).

Physical examination includes checking:

- Vital signs – temperature, respiratory rate, pulse rate and rhythm and blood pressure.
- Signs of poorer prognosis – confusion, reduced conscious level, cachexia, respiratory distress, cyanosis and evidence of cor-pulmonale.
- Evidence of co-morbid conditions – cardiovascular and neurovascular diseases, diabetes mellitus and lung cancer.

8.5.2 Spirometry and Peak Flow Readings

These tests are difficult to be carried out by patients and to be interpreted during AECOPD.^{69 (Level III)} The measurements are not accurate and therefore their routine testing during the acute phase of AECOPD is not recommended. However, spirometry may be performed after the patient has recovered either before hospital discharge or on a follow-up clinic visit especially if they have not done it before.

8.5.3 Pulse Oximetry

Pulse oximetry is used to evaluate the patient's oxygen saturation (SpO₂), need for supplemental oxygen and response to treatment and to guide further management. Oxygen supplementation should be given if SpO₂ < 90%.^{69 (Level III)} If arterial blood gas results are not readily available, controlled oxygen therapy using Venturi mask is recommended to avoid CO₂ narcosis, aiming for SpO₂ ≥ 90%. Morbidity and mortality are increased in patients with hypercapnic respiratory failure when the SpO₂ is increased to above 93-95%.^{224 (Level III)} However, pulse oximetry does not provide information about CO₂ levels.

8.5.4 Arterial Blood Gas Measurement

Arterial blood gas measurement is useful as a tool to assess the severity of AECOPD. It is recommended for patients attending the accident and emergency department and also in those who are hospitalised. It should be performed in unwell patients despite them having good SpO₂ levels. In patients who are breathing room air, respiratory failure is defined as PaO₂ < 8.0 kPa (60 mmHg) and/or SaO₂ < 90% with or without PaCO₂ > 6.7 kPa (50 mmHg). The respiratory failure and exacerbation is worse if there is respiratory acidosis [pH < 7.36 with hypercapnia pCO₂ 6 - 8 kPa (45 - 60 mmHg)] and is an indication for assisted (non-invasive or invasive ventilation) ventilation.^{69 (Level III)} It should also be considered in patients who do not respond to initial medical treatment.

8.5.5 Sputum Gram Stain and Culture

In an outpatient setting, if an AECOPD is infectious in nature and does not respond to initial antibiotic therapy, sputum culture and sensitivity should be performed.^{69 (Level III)} Sputum examination should also be performed on patients who are hospitalised^{225 (Level II-3)} or whose chest radiographs show changes suggestive of pneumonia.

8.5.6 Chest Radiograph

A chest radiograph is useful to identify possible causes of the AECOPD (for example, pneumonia), alternative diagnoses that may mimic features of COPD (for example, heart failure and bronchiectasis) and possible complications (for example, lung cancer and pneumothorax).

8.5.7 Electrocardiogram (ECG)

An ECG is a valuable tool for the diagnosis of tachyarrhythmias, myocardial ischaemia and right ventricular hypertrophy.

8.5.8 Other Laboratory Tests

Full blood count:

A raised total white blood cell count may indicate underlying sepsis but a normal count does not rule it out. The presence of purulent sputum in AECOPD is enough to commence empirical antibiotic therapy.^{226 (Level III)} Polycythaemia and raised haematocrit levels suggest cor pulmonale. Anaemia could be due to underlying chronic disease, malnutrition or blood loss.

Renal profile, blood glucose and liver function test:

Biochemical abnormalities may be present during AECOPD. These additional tests may reveal the presence of co-morbid conditions such as renal impairment, uncontrolled diabetes and malnutrition.

8.6 Differential Diagnoses

Non-compliance to medications may mimic an exacerbation, therefore careful history taking is necessary. If patients do not respond to standard therapy, they need to be reassessed to determine if they have other diagnoses that may imitate or aggravate their AECOPD such as:

- Asthma (may co-exist with COPD)
- Bronchiectasis
- Diffuse parenchymal lung disease
- Lung cancer
- Pulmonary embolism
- Pneumothorax
- Heart failure.

Patients with advanced COPD often have several co-morbid conditions.^{128 (Level I), 204 (Level III)}

8.7 Managing Acute Exacerbations of COPD

The aims of management in exacerbations of COPD are to:

1. Relieve symptoms and airflow obstruction
2. Maintain adequate oxygenation
3. Treat any co-morbid conditions that may contribute to the respiratory deterioration or treat any precipitating factor such as infection.

Most patients with AECOPD are treated in the primary care setting but a minority of patients will require hospital assessment or admissions. Indications for hospital assessment or admissions for AECOPD are shown in **Table 8-1**.

Table 8-1: Indications for Hospital Assessment or Admission for Acute Exacerbations of COPD

- | | |
|---|---|
| <ul style="list-style-type: none">• Marked increase in intensity of symptoms such as sudden development of dyspnoea• Underlying severe COPD• Development of new physical signs e.g., cyanosis, peripheral oedema• Haemodynamic instability | <ul style="list-style-type: none">• Reduced alertness• Failure of exacerbation to respond to initial medical management• Significant co-morbidities• Newly occurring cardiac arrhythmias• Older age• Insufficient home support |
|---|---|

8.8 Home Management (Refer Figure 8-1)

8.8.1 Bronchodilator Therapy

Inhaled bronchodilators improve airflow obstruction and reduce lung hyperinflation, thereby improving dyspnoea. Short-acting inhaled β_2 -agonists are preferred for treating AECOPD.^{76,196 (Level III), 227 (Level I)} The dosage and frequency of existing short-acting β_2 -agonists therapy should be increased, for example, salbutamol 200-400 μg or terbutaline 500 μg every 3-4 hours. Anticholinergic therapy (ipratropium bromide 40 μg 6 hourly) may be added if not yet in use, until the symptoms improve.

8.8.2 Systemic Corticosteroids

Systemic corticosteroids should be used in addition to existing bronchodilator therapy in an AECOPD with significant increase in dyspnoea or if the patient's baseline FEV₁ is < 50% predicted. Systemic corticosteroids have been shown to shorten recovery time, improve oxygenation and lung function and reduce treatment failure.^{228 (Level I)} A dose of 30-40 mg prednisolone per day for 7-14 days is appropriate for most patients.^{69,204 (Level III)} There is no advantage in prolonged corticosteroid therapy as the risk of side effects is significant.

8.8.3 Antibiotics

The use of antibiotics is discussed in **8.9.4** under hospital management.

8.9 Hospital Management (Refer Figure 8-2)

The initial management of a patient with an AECOPD in the emergency department is to provide controlled oxygen therapy and assessing the severity of the exacerbation to determine if the patient can be treated in the emergency department or in the general ward. If the exacerbation is life threatening, the patient should be admitted to a high dependency unit or the ICU.

8.9.1 Controlled Oxygen Therapy

Supplemental oxygen therapy is considered the cornerstone of hospital treatment for an AECOPD. Oxygen therapy is given to maintain adequate oxygenation ($\text{PaO}_2 \geq 8 \text{ kPa}$ or $\geq 60 \text{ mmHg}$ or $\text{SpO}_2 \geq 90\%$) without precipitating respiratory acidosis or worsening hypercapnia. Controlled oxygen therapy should be given in the form of 24-28% oxygen via a Venturi mask if available to ensure accurate delivery of oxygen or 1-2 litres per minute of oxygen via nasal prongs.^{76,196 (Level III)} Arterial blood gases should be checked 30-60 minutes later to ensure adequate oxygenation without CO_2 retention or acidosis. Arterial blood gases should be monitored regularly depending on the clinical state of the patient (**Figure 8-3**).

Figure 8-1: Algorithm for Managing Acute Exacerbations of COPD: Home Management




Figure 8-2: Algorithm for Managing Acute Exacerbations of COPD: Hospital Management





Figure 8-3: Algorithm for Adjustment of Supplemental Oxygen Settings During Acute Exacerbations of COPD



8.9.2 Bronchodilator Therapy

The relief of airflow obstruction by bronchodilator therapy is the major goal in the treatment of AECOPD. Inhaled SABA is usually given in the nebulised form although there is evidence that administration of inhaled SABA via a metered dose inhaler (10 to 20 puffs via a spacer device) has equal efficacy to nebulised treatment.^{76,196 (Level III), 227 (Level I)} The use of nebulisers poses a risk of nosocomial infection to healthcare workers and other patients.^{229 (Level III)} Extra precautions should be taken to reduce the risk of transmitting respiratory infections such as influenza A (H1N1). In severe exacerbations, nebulised SABA can be combined with a SAAC, for example, Combivent® nebuliser solution 2.5 mL (ipratropium bromide 500 µg, salbutamol 2.5 mg) 6 hourly or Duovent® nebuliser solution 4 mL (ipratropium bromide 500 µg, fenoterol 1.25 mg) 6 hourly.

In severe exacerbations, intravenous methylxanthines can be considered if there is inadequate response to inhaled SABA and SAAC.^{230 (Level II-1)} The recommended loading dose of intravenous aminophylline is 250-500 mg (5 mg/kg) over 20 minutes followed by a maintenance dose of 500 µg/kg/hour, adjusted according to plasma theophylline concentration (10–20 mg/L or 55–110 µmol/L). Patients already on maintenance theophylline treatment should not be given a loading dose. Doctors need to be aware of interactions between aminophylline with various other drugs.

8.9.3 Systemic Corticosteroids

Corticosteroids are effective treatments for AECOPD and are recommended as an addition to other therapies in the hospital management of AECOPD in the absence of significant contraindications. Systemic corticosteroids improve lung function over the first 72 hours, shorten hospital stay and reduce treatment failure over the subsequent 30 days.^{231,232 (Level I)} A dose of 30-40 mg of oral prednisolone daily for 7-14 days appears to be safe and effective. A study has shown that nebulised corticosteroids may also be beneficial during AECOPD as an alternative to oral prednisolone in the treatment of non-acidotic exacerbations of COPD.^{233 (Level I)} Systemic corticosteroids should be discontinued after the acute episode as they are associated with significant side-effects.

8.9.4 Antibiotics

Bacterial lower respiratory tract infections, either primary or secondary, following an initial viral infection are a common cause of AECOPD. Antibiotics are beneficial during AECOPD but have no proven benefit to prevent exacerbations.^{234 (Level I), 235 (Level III)}

Antibiotics should be given to patients with AECOPD having at least 2 out of 3 cardinal symptoms (i.e., purulent sputum, increased sputum volume and/or increased dyspnoea).^{226 (Level III)} Patients with a severe AECOPD that requires invasive or non-invasive ventilation should also be covered with antibiotics.^{236 (Level I)} The risk factors for *Pseudomonas aeruginosa* infection include severe airflow limitation, recent hospitalisation (in the last 3 months), frequent administration of antibiotics (4 courses in the last year), severe AECOPD and isolation of *Pseudomonas aeruginosa* during a previous AECOPD or colonisation during the stable period.^{69 (Level III)} The choice of antibiotics depends on the local antibiotic policy (**Table 8-2**).

Table 8-2: Antibiotic Treatment for Acute Exacerbations of COPD(Adapted from the National Antibiotic Guideline 2008, Ministry of Health of Malaysia²³⁷)

Stable clinical state	Symptoms of exacerbation and risk factors	Probable bacterial pathogen	Suggested treatment
Simple COPD (without risk factors)	Increased cough and sputum volume, purulent sputum and increased dyspnoea	<i>Haemophilus influenzae</i> , <i>Moraxella catarrhalis</i> , <i>Streptococcus pneumoniae</i> , Atypical respiratory pathogens	<p>Preferred Extended spectrum macrolide e.g., azithromycin 500 mg once daily for 3 days, clarithromycin 250 mg twice daily for 7 days OR 2nd or 3rd generation cephalosporin e.g., cefuroxime 250-500 mg twice daily for 7 days</p> <hr/> <p>Alternative β-lactam/β-lactamase inhibitor e.g., Amoxicillin/clavulanate 625 mg twice daily for 7 days OR Erythromycin ethylsuccinate 800 mg twice daily for 7 days OR Doxycycline 100 mg twice daily for 7 days OR Moxifloxacin 400 mg once daily for 5-7 days</p>
Complicated COPD (with risk factors) *	<p>As in COPD without risk factors plus at least one of the following:</p> <ul style="list-style-type: none"> • FEV₁ < 50% predicted • > 4 exacerbations/year • > 65 years old • Significant co-morbidity (especially heart disease) • Use of home oxygen • Chronic oral corticosteroid use • Antibiotic use in the past 3 months 	<i>Haemophilus influenzae</i> , <i>Moraxella catarrhalis</i> , <i>Streptococcus pneumoniae</i> , Atypical respiratory pathogens, <i>Klebsiella spp.</i> , <i>Pseudomonas aeruginosa</i> , Other Gram-negatives	<p>Preferred β-lactam ± β-lactamase inhibitor e.g. amoxicillin 1 g three times a day or amoxicillin/clavulanate 2 g twice daily for 7 days OR 2nd or 3rd generation cephalosporin e.g., cefuroxime 500 mg twice daily, ceftriaxone 1 g once daily for 7 days OR/AND Extended spectrum macrolide e.g., azithromycin 500 mg once daily for 3-5 days ** Patients at risk for <i>Pseudomonas aeruginosa</i> infection should receive anti-<i>Pseudomonas</i> antibiotics</p> <hr/> <p>Alternative Fluoroquinolone e.g., levofloxacin 750 mg once daily for 5 days, moxifloxacin 400 mg once daily for 5-7 days, ciprofloxacin 250-500 mg twice daily for 5-7 days</p>

* May require parenteral therapy. Consider referral to hospital.

8.9.5 Other Measures

Further hospital management includes:

- Monitoring of fluid balance
- Deep vein thrombosis prophylaxis with subcutaneous heparin especially in immobile patients and those with acute on chronic respiratory failure^{238 (Level III), 239 (Level II-2)}
- Supplementary nutrition^{240 (Level II-2)}
- Sputum clearance.^{241 (Level III)}

There is no convincing evidence to support the routine use of pharmacological mucus clearance strategies.^{69 (Level III)} Chest physiotherapy has no proven value during exacerbations unless a large amount of sputum is produced (> 25 mL per day) or there is mucus plugging with lobar atelectasis.^{69 (Level III)}

Diuretics are indicated if there is evidence of peripheral oedema.

8.10 Management of Severe but Not Life-Threatening AECOPD in the Emergency Department or the Hospital

- Assess severity of symptoms, blood gases, chest radiograph
- Administer controlled oxygen therapy, repeat arterial blood gas measurements after 30 minutes
- Bronchodilators
 - o Increase dose frequency
 - o Combine inhaled SABA and SAAC
 - o Use spacers or air-driven nebulisers
 - o Consider adding intravenous aminophylline, if needed
- Oral or intravenous glucocorticosteroids
- Antibiotics when signs of bacterial infection are present
- Consider non-invasive/invasive mechanical ventilation if patient's condition deteriorates
- At all times:
 - o Monitor fluid balance and nutrition
 - o Consider subcutaneous heparin
 - o Identify and treat associated conditions (e.g. heart failure, arrhythmias)
 - o Monitor patient's condition closely.

Recommendations: Drug Treatment for AECOPD

1. Inhaled bronchodilators and systemic corticosteroids are effective treatments for exacerbations of COPD. *[Grade A]*
2. Antibiotics should be used in patients with signs of airway infection (i.e., change in sputum colour, increased sputum volume and/or increased dyspnoea). *[Grade A]*

8.11 Non-invasive Ventilation

In patients with COPD and acute respiratory failure, the use of non-invasive ventilation (NIV) results in less frequent intubation, decreased complications and mortality as well as a shorter hospital stay.^{242 (Level I)}

The primary indication is persistent hypercapnoeic respiratory failure despite optimal medical therapy. It is recommended that NIV should be delivered in a dedicated setting with staff who have been trained in its application, are experienced in its use and are aware of its limitations. When patients are started on NIV there should be a clear plan covering what to do in the event of deterioration and the agreed ceilings of therapy.^{243 (Level III)}

Table 8-3: Indications for NIV^{69 (Level III)}:

- Moderate to severe dyspnoea with use of accessory muscles and paradoxical abdominal motion.
- Respiratory rate > 25 breaths per minute.
- Moderate to severe acidosis (pH 7.25 - 7.35) and/or hypercapnia [$\text{PaCO}_2 > 6.0 \text{ kPa}$ (45 mmHg)].

Table 8-4: Contraindications for NIV^{69 (Level III)}:

- Respiratory arrest
- Cardiovascular instability (hypotension, arrhythmias, myocardial infarction)
- At high risk for aspiration
- Impaired mental status; uncooperative patient
- Significant facial injury
- Viscous or copious secretions
- Recent facial or gastroesophageal surgery
- Fixed nasopharyngeal abnormalities
- Burns
- Extreme obesity
- Underlying intestinal obstruction.

8.12 Invasive Mechanical Ventilation

The use of invasive ventilation is influenced by the likely reversibility of the precipitating event, the patient's wishes (or advance directive) and the availability of intensive care facilities.

Table 8-5: Indications for Invasive Mechanical Ventilation⁶⁹ (Level III):

- Unable to tolerate NIV or NIV failure
- Severe dyspnoea with use of accessory muscles and paradoxical abdominal motion
- Respiratory rate > 35 breaths per minute
- Severe acidosis (pH < 7.25) and/or hypercapnia [PaCO₂ > 8.0 kPa, (60 mmHg)]
- Respiratory arrest
- Impaired mental status; somnolence
- Cardiovascular instability (hypotension, shock)
- Other complications (metabolic abnormalities, sepsis, pneumonia, pulmonary embolism, barotrauma, massive pleural effusion)

Recommendations: Ventilatory Support

1. NIV should be considered for AECOPD patients with hypercapnic respiratory failure despite optimal medical therapy. [Grade A]
2. Patients with severe AECOPD requiring NIV should be managed by dedicated and trained staff in high dependency or intensive care units. [Grade C]

8.13 Hospital Discharge⁶⁹ (Level III)

Patients with AECOPD can be discharged when:

- Inhaled bronchodilator therapy is required not more frequently than every 4 hours
- Patient, if previously ambulatory, is able to walk across the room
- Patient is able to eat and sleep without frequent awakening by dyspnoea
- Patient has been clinically stable for 12-24 hours
- ABG or SpO₂ have been stable for at least 12-24 hours
- Patient (or home caregiver) understands the disease and its management (including correct use of medications) at home
- Follow-up has been organised.

A copy of discharge summary should be given to the patient. A close working relationship between hospital and primary care doctors is desirable.

8.14 Follow Up⁶⁹ (Level III)

Patients should be reviewed within 8 weeks after discharge. The following should be assessed²⁴⁴ (Level II-2):

- Ability to cope in the patient's usual environment
- Spirometry measurement
- Inhaler technique
- Understanding of recommended treatment regimen
- Smoking status and cessation
- Need for LTOT and/or home nebuliser (for patient with stage IV COPD)
- Suitability for pulmonary rehabilitation
- Vaccination with influenza vaccine with or without pneumococcal vaccine
- Self-management plans and future monitoring.

SECTION 9 TRANSLATING GUIDELINE RECOMMENDATIONS TO THE CONTEXT OF PRIMARY CARE

9.1 Introduction

Primary care provides the first point of contact for medical care delivery. Most patients with COPD are seen in primary care and it is therefore paramount that primary care physicians are adept in identifying, managing and preventing COPD. The best practice recommendations are detailed in **Sections 1 to 8** and require effective translation of such recommendations to individual circumstances in the primary care setting. In Malaysia, the main providers of primary care are the public health centres, hospital-based primary care outpatient clinics and private general practice. The factors that are particularly pertinent in this context are described in this section.

9.2 Early Diagnosis

Early identification of patients at high risk is an important role for primary care doctors. Such identification allows intervention to be taken such as smoking cessation, reduction of exposure to tobacco smoke as well as other risk factors such as occupational dusts, indoor and outdoor pollution.

Diagnosis should be made based on at risk individuals with symptoms of chronic cough, increased sputum production, or breathlessness, confirmed by spirometry. However, it is not recommended to use spirometry for the purpose of screening all adults for COPD. Therefore spirometry should be used as a diagnostic test for patients identified as at risk.^{245 (Level III)}

9.3 Smoking Cessation

To date, smoking cessation is the only effective way of preventing the development and reducing the progression of COPD. Smoking cessation interventions, which include brief behavioural sessions and pharmacotherapy, are effective in making patients quit smoking.^{246 (Level III)} All individuals with COPD who still smoke will benefit from smoking cessation.

9.4 Spirometry

In primary care, COPD is diagnosed mainly on clinical grounds alone. However, the diagnosis can be easily overlooked and the condition therefore is frequently under-diagnosed.

Spirometry is strongly advocated for the confirmation of diagnosis and the assessment of COPD severity. The training in execution and correct interpretation of the spirometry is therefore necessary. In sites where spirometry is not available, referral to other centres where this test can be performed should be arranged. Peak expiratory flow measurement may be considered where spirometry is not available.^{247 (Level III)} However, while low peak expiratory flow rates (PEFR) with little or no bronchodilator reversibility are consistent with COPD, but such findings can also be due to other lung diseases. Furthermore, PEFR is only reduced in advanced COPD. Therefore, it is important to realise that spirometry is now the choice investigation for diagnosis and assessing severity.

9.5 Long-Term Management

COPD is a chronic disease. The role of primary care doctors include the following:

- Education and counselling on COPD, and how it is different from asthma
- Raising awareness of COPD and that cigarette smoking cessation and avoidance of other risk factors can help to prevent the development and progression of COPD

- Preventing exacerbations, such as by risk factor avoidance, vaccination and appropriate pharmacotherapy
- Coordinating care with hospital-based specialists in issues of selection of therapies, prevention and treatment of exacerbations, treatment of co-morbidities and complications such as cor pulmonale. Of particular relevance are the awareness of availability of pulmonary rehabilitation as well as the assessment of the need for and prescribing of LTOT
- Dealing with problems in relation to home caregivers, such as coping with the disease, provision of support and dealing with end-of-life issues especially when the disease is advanced
- Encouraging patients to maintain the best level of physical activity.

9.6 When to Refer to Hospital-Based Specialists?

Referral to a hospital-based specialist should be considered in the following situations:

- When the diagnosis is in doubt
- For spirometry testing when such a facility is not available on site
- Onset of cor pulmonale
- Assessment and prescribing of LTOT
- When there is a rapid decline of FEV₁ indicating severity of the disease
- Patient aged < 40 years in whom an underlying genetic predisposition such as alpha-1 antitrypsin deficiency is suspected
- When access to certain drugs is a problem.

Recommendations: Translating Guideline Recommendations to the Context of Primary Care

1. Early identification of patients at risk for COPD and smoking cessation is important in primary care. *[Grade A]*
2. Spirometry is now strongly advocated for the confirmation of diagnosis and the assessment of COPD severity. *[Grade A]*
3. All COPD patients who smoke should be advised and assisted to stop smoking. *[Grade A]*
4. COPD is a chronic disease that should be jointly managed whenever necessary between primary care and hospital-based doctors. This includes managing exacerbations and prescribing LTOT. *[Grade A]*

GLOSSARY OF TERMS

AECOPD	Acute Exacerbation of Chronic Obstructive Pulmonary Disease
BMI	Body Mass Index
BODE	Body mass index (BMI), airflow Obstruction, Dyspnoea and Exercise capacity
BUSECr	Blood Urea, Serum Electrolytes and Creatinine
COPD	Chronic Obstructive Pulmonary Disease
CPAP	Continuous Positive Airway Pressure
CXR	Chest X-Ray
C&S	Culture and Sensitivity
DALYs	Disability-Adjusted Life Years
DLCO	Diffusing capacity of the Lungs for Carbon Monoxide
DVT	Deep Vein Thrombosis
ECG	Electrocardiogram
EUROSCOP	European Respiratory Society study on chronic obstructive disease
FBC	Full Blood Count
FCTC	Framework Convention on Tobacco Control
FEV₁	Forced Expiratory Volume in the first second
FiO₂	Fraction of Inspired Oxygen
FVC	Forced Vital Capacity
HDAC	Histone Deacetylase
HRQoL	Health-Related Quality of Life
ICS	Inhaled Corticosteroid
ICU	Intensive Care Unit
INSPIRE	Investigating New Standards for Prophylaxis in Reducing Exacerbations
ISOLDE	Inhaled Steroids in Obstructive Lung Disease
LAAC	Long-Acting Anticholinergic
LABA	Long-Acting β_2 -Agonist
LFT	Liver Function Test
LTOT	Long-term Oxygen Therapy
LVRS	Lung Volume Reduction Surgery
MDI	Metered Dose Inhaler
MMRC	Modified Medical Research Council
6MWT	Six Minute Walk Test
NIV	Non-Invasive Ventilation
NRT	Nicotine Replacement Therapy
NYHA	New York Heart Association
OPTIMAL	The Canadian Optimal Therapy of COPD Trial
PaCO₂	Arterial partial pressure of carbon dioxide
PaO₂	Arterial partial pressure of oxygen
PDE₄	Phosphodiesterase-4
PEFR	Peak Expiratory Flow Rate
pMDI	Pressurised Metered Dose Inhaler
PRN	As needed
PPV23	23-Valent Polysaccharide Vaccine
QoL	Quality of Life
SAAC	Short-Acting Anticholinergic
SABA	Short-Acting β_2 -Agonist
SAFE	SGRQ score, Air-Flow limitation and Exercise tolerance
SaO₂	Arterial oxygen saturation
SpO₂	Oxygen saturation by pulse oximetry
TNF	Tumour Necrosis Factor
TORCH	TOwards a Revolution in COPD Health
UPLIFT	Understanding Potential Long-term Impacts on Function with Tiotropium

ACKNOWLEDGEMENTS

The working group members of these guidelines would like to express their gratitude and appreciation to the following for their contributions:

- **Panel of external reviewers who reviewed the draft**
- **Technical Advisory Committee for Clinical Practice Guidelines for their valuable input and feedback**
- **Health Technology Assessment Section, Ministry of Health**
- **CMPMedica for their editorial and secretariat services.**

DISCLOSURE STATEMENT

The panel members have completed disclosure forms. None of them hold shares in pharmaceutical firms or acts as consultants to such firms. (Details are available upon request from the CPG secretariat)

SOURCES OF FUNDING

The development of the CPG was supported by unconditional educational grants from AstraZeneca, Boehringer Ingelheim and GlaxoSmithKline. The final recommendations made by the Guideline Development Group have not been influenced by the views or interests of any funding body.

REFERENCES

1. Agustí AG. Systemic effects of chronic obstructive pulmonary disease. *Proc Am Thorac Soc* 2005; 2:367-370.
2. Soriano JB, Visick GT, Muellerova H, et al. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. *Chest* 2005; 128:2099-2107.
3. Similowski T, Agustí AG, MacNee W, Schonhofer B. The potential impact of anaemia of chronic disease in COPD. *Eur Respir J* 2006; 27:390-396.
4. Gan WQ, Man SF, Senthilvelan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. *Thorax* 2004; 59:574-580.
5. Van Weel C, Schellevis FG. Comorbidity and guidelines: conflicting interests. *Lancet* 2006; 367:550-551.
6. Stavem K, Aaser E, Sandvik L, et al. Lung function, smoking and mortality in a 26-year follow-up of healthy middle-aged males. *Eur Respir J* 2005; 25:618-625.
7. Skillrud DM, Offord KP, Miller RD. Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. *Ann Intern Med* 1986; 105:503-507.
8. Tockman MS, Anthonisen NR, Wright EC, Donithan MG. Airways obstruction and the risk for lung cancer. *Ann Intern Med* 1987; 106:512-518.
9. Lange P, Nyboe J, Appleyard M, et al. Ventilatory function and chronic mucus hypersecretion as predictors of death from lung cancer. *Am Rev Respir Dis* 1990; 141:613-617.
10. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. *Eur Respir J* 2005; 26:948-968.
11. Guidelines of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease; updated in 2008. Available at: <http://www.copdgold.org>. Accessed 1 September 2009.
12. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2008 update – highlights for primary care. *Can Respir J* 2008; 15:1A-8A.
13. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. *Chest* 1988; 93:580-586.
14. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. *New Engl J Med* 2004; 350:1005-1012.
15. American Thoracic Society. ATS statement: guidelines for the six-minute-walk test. *Am J Respir Crit Care Med* 2002; 166:1111-1117.
16. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. *Lancet* 2004; 364:709-721.
17. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. *Eur Respir J* 2003; 22:672-688.
18. Burgel PR, Nadel JA. Roles of epidermal growth factor receptor activation in epithelial cell repair and mucin production in airway epithelium. *Thorax* 2004; 59:992-996.
19. Barbera JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. *Eur Respir J* 2003; 21:892-905.
20. Chen JC, Mannino DM. Worldwide epidemiology of chronic obstructive pulmonary disease. *Curr Opin Pulm Med* 1999; 5:93-99.
21. Hurd S. The impact of COPD on lung health worldwide. *Chest* 2000; 117:1S-4S.
22. Pauwels RA, Buist AS, Calverley PMA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. *Am J Respir Crit Care Med* 2001; 163:1256-1276.
23. Mathers C, Murray CJL, Lopez AD, et al. The global burden of diseases 2000 project: objectives, methods, data sources and preliminary results. Global Programme on Evidence for Health Policy, World Health Organization, 2001.
24. Murray CJL, Lopez AD. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Harvard University Press, Cambridge, MA, 1996.
25. Murray CJL, Lopez AD. Global mortality, disability, and the contribution of risk factors: global burden of disease study. *Lancet* 1997; 349:1436-1442.
26. Murray CJL, Lopez AD. Evidence-based health policy—lessons from the global burden of disease study. *Science* 1996; 274:740-743.
27. World Health Organization. Updated Projections of Global Mortality and Burden of Disease, 2002–2030: Data Sources, Methods and Results. Evidence and Information for Policy. 2005. Available from: <http://www.who.int/healthinfo/statistics/>. Accessed: 31 August 2009.
28. Hansell AL, Walk JA, Soriano JB. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. *Eur Respir J* 2003; 22:809-814.
29. Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. *Chest* 2005; 128:2640-2646.
30. Holguin F, Folch E, Redd SC, et al. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. *Chest* 2005; 128:2005-2111.
31. He J, GuD, Wu X, et al. Major causes of death among men and women in China. *N Engl J Med* 2005; 353:1124-1134.

32. Regional COPD Working Group. Trends in COPD mortality and hospitalizations in countries and regions of Asia-Pacific. *Respirology* 2009; 14:90-97.
33. Takemura H, Hida W, Sasaki T, et al. Prevalence of chronic obstructive pulmonary disease in Japanese people on medical check-Up. *Tohoku J Exp Med* 2005; 207:41-50.
34. Kim DS, Kim YS, Jung KS, et al. Prevalence of chronic obstructive pulmonary disease in Korea: a population based spirometry survey. *Am J Respir Crit Care Med* 2005; 172:842-847.
35. Regional COPD Working Group. COPD prevalence in 12 Asia-Pacific countries and regions: projections based on the COPD prevalence estimation model. *Respirology* 2003; 8:192-198.
36. Institute of Public Health, National Institute of Health, MOH Malaysia. Malaysian Burden of Disease and Injury Study 2004; 86-87.
37. Aljunied SM. Malaysia's Projected Health Care Cost Of Three Smoking Related Diseases: 2004-2010, 2007.
38. Lokke A, Lange P, Scharling H, et al. Developing COPD: a 25 year follow up study of the general population. *Thorax* 2006; 61:935-939.
39. The Health Consequences of Smoking: A Report of the Surgeon General. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004.
40. Blanco I, de Serres FJ, Fernandez-Bustillo E, et al. Estimated numbers and prevalence of P1*S and P1*Z alleles of alpha-1 antitrypsin deficiency in European countries. *Eur Respir J* 2006; 27:77-84.
41. McCloskey SC, Patel BD, Hinchliffe SJ, et al. Sibling of patients with severe chronic obstructive pulmonary disease have a significant risk of airflow obstruction. *Am J Respir Crit Care Med* 2001; 64:1419-1424.
42. Burrow B, Knudson RJ, Cline MG, Lebowitz MD. Quantitative relationships between cigarette smoking and ventilator function. *Am Rev Respir Dis* 1977; 115:195-205.
43. US Surgeon General. The health consequences of smoking; chronic obstructive pulmonary disease. Washington DC. US Department of Health and Human Services; 1984.
44. Leuenberger P, Schwartz J, Ackermann-Liebrich U, et al. Passive smoking exposure in adults and chronic respiratory symptoms (SAPALDIA Study). Swiss Study on Air Pollution and Lung Diseases in Adults, SAPALDIA Team. *Am J Respir Crit Care Med* 1994; 150:1222-1228.
45. Dayal HH, Khuder S, Sharrar R, Trieff N. Passive smoking in obstructive respiratory disease in an industrialized urban population. *Environ Res* 1994; 65:161-171.
46. Tager IB, Jgo L, Hanrahan JP. Maternal smoking during pregnancy. Effects on lung function during the first 18 months of life. *Am J Respir Crit Care Med* 1995; 152:977-983.
47. Rodriguez E, Ferrer J, Marti S, et al. Impact of Occupational Exposure on Severity of COPD *Chest* 2008; 134:1237-1243.
48. Eduard W, Pearce N, Douwes J. Chronic Bronchitis, COPD, and Lung Function in Farmers *Chest* 2009, doi:10.1378/chest.08-2192. Published ahead of print.
49. Smith KR. Inaugural article: national burden of disease in India from indoor air pollution. *Proc Natl Acad Sci USA* 2000; 97:13286-13293.
50. Chan-Yeung M, Ait-Khaled N, White N, et al. The burden and impact of COPD in Asia and Africa. *Int J Tuberc Lung Dis* 2004; 8:2-14.
51. Warwick H, Doig A. Smoke the killer in the kitchen: Indoor air pollution in developing countries ITDG Publishing, 103-105 Southampton Row, London WC1HLD, UK 2004:URL: http://www.ehw.org/Healthy_House/documents/kitchensmoke.pdf. Accessed: 8 October 2009.
52. Mishra V, Dai X, Smith KR, Mika L. Maternal exposure to biomass smoke and reduced birth weight in Zimbabwe. *Ann Epidemiol* 2004; 14:740-747.
53. Boman C, Forsberg B, Sandstrom T. Shedding new light on wood smoke: a risk factor for respiratory health. *Eur Respir J* 2006; 27:446-447.
54. Orozco-Levi M, Garcia-Aymerich J, Villar J, et al. Wood smoke exposure and risk of chronic obstructive pulmonary disease. *Eur Respir J* 2006; 27:542-546.
55. Abbey DE, Burchette RJ, Knutsen SF, et al. Long-term particulate and other air pollutants and lung function in nonsmokers. *Am J Respir Crit Care Med* 1998;158:289-298.
56. Lawlor DA, Ebrahim S, Davey Smith G. Association of birth weight with adult lung function: findings from the British Women's Heart and Health Study and ameta-analysis. *Thorax* 2005; 60:851-858.
57. MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. *Proc Am Thorac Soc* 2005; 2:50-60.
58. Silverthorn EK, Weiss ST, Drazen JM, et al. Gender-related differences in severe, early onset chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2000; 162:2152-2158.
59. Retamales I, Elliott WM, Meshi B, et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. *Am J Respir Crit Care Med* 2001; 164:469-473.

60. Sethi S, Maloney J, Grove L, et al. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2006; 173:991-998.
61. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2001; 164:1618-1623.
62. Sanjay Sethi. Bacterial Infection and the Pathogenesis of COPD. *Chest* 2000; 117:286S-291S.
63. Prescott E, Lange P, Vest J. Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study. *Eur Respir J* 1999; 13:1109-1114.
64. Tao X, Hong CJ, Yu S, et al. Priority among air pollution factors for preventing chronic obstructive pulmonary disease in Shanghai. *Sci Total Envir* 1992; 127:57-67.
65. US Centers for Disease Control and Prevention. Criteria for a recommended standard: occupational exposure to respirable coal mine dust: National Institute of Occupational Safety and Health; 1995.
66. Calverley P, Bellamy D. The challenge of providing better care for patients with chronic obstructive pulmonary disease: The poor relation of airways obstruction? *Thorax* 2000; 55:78-82.
67. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. *Am J Respir Crit Care Med* 2002; 166:675-679.
68. Anthonisen NR, Connett JE, Kiley JP et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV₁. The Lung Health Study. *JAMA* 1994; 272:1497-1505.
69. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management and prevention of chronic obstructive pulmonary disease. Bethesda, MD: National Heart, Lung and Blood Institute, April 2001 (revised 2008). Available at <http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=2003>. Accessed: 8 October 2009.
70. Asia Pacific COPD Roundtable Group: Global strategy for diagnosis, management and prevention of chronic obstructive pulmonary disease: an Asia Pacific perspective. *Respirology* 2005; 10:9-17.
71. Kelly CA, Gibson GJ. Relation between FEV₁ and peak expiratory flow in patients with chronic obstructive pulmonary disease. *Thorax* 1988; 43:335-336.
72. Schols AM, Soeters PB, Dingemans AM, et al. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. *Am Rev Respir Dis* 1993; 147:1151-1156.
73. Calverley PMA. Neurophysiological deficits in chronic obstructive pulmonary disease. *Monaldi Arch Chest Dis* 1996; 51:5-6.
74. Walker PP, Mitchell P, Diamante F, et al. Effect of primary care spirometry on the diagnosis and management of COPD. *Eur Respir J* 2006; 28:945-952.
75. Aggarwal AN, Gupta D, Jindal SK. The relationship between FEV₁ and peak expiratory flow in patients with airways obstruction is poor. *Chest* 2006; 130:1454-1461.
76. Rabe KF, Hurd S, Anzueto A, et al. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 2007; 176: 532-555.
77. Calverley PM, Burge PS, Spencer S, et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. *Thorax* 2003; 58:659-664.
78. Gibson GJ, MacNee W. Chronic obstructive pulmonary disease: Investigations and assessment of severity. *Eur Respir Mon* 2006; 38:24-40.
79. Cote CG, Pinto-Plata VM, Marin JM, et al. The modified BODE index: validation with mortality in COPD. *Eur Respir J* 2008; 32:1269-1274.
80. Mohd Shah A, Mohd Anshar F, Mohd Perdaus AF, et al. The SAFE (SGRQ score, air-flow limitation and exercise tolerance) Index: a new composite score for the stratification of severity in chronic obstructive pulmonary disease. *Postgrad Med J* 2007; 83:492-497.
81. ATS statement: guidelines for the six-minute walk test. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. *Am J Respir Crit Care Med* 2002; 166:111-117.
82. Casanova C, Cote CG, Marin JM, et al. The 6 min walking distance: Long term follow up in patients with COPD. *Eur Respir J* 2007; 29:535-540.
83. Roberts CM, Bugler JR, Melchor R, et al. Value of pulse oximetry in screening for long term oxygen therapy requirement. *Eur Respir J* 1993; 6:559-562.
84. Jaakkola MS, Jaakkola JJ. Impact of smoke free workplace legislation on exposures and health: possibilities for prevention. *Eur Respir J* 2006; 28:397-408.
85. Jindal SK, Aggarwal AN, Choudhry K, et al. A multicentric study on epidemiology of chronic obstructive pulmonary disease and its relationship with tobacco smoking and environmental tobacco smoke exposure. *Indian J Chest Dis Allied Sci* 2006; 48:23-29.
86. Eisner MD, Balmes J, Katz BP, et al. Lifetime environmental tobacco smoke exposure and the risk of chronic obstructive pulmonary disease. *Environ Health Perspect* 2005; 4:7-15.
87. The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General, Department of Health and Human Services. Washington, DC, US; 2006.

88. Colley JR, Holland WW, Corkhill RT. Influence of passive smoking and parental phlegm on pneumonia and bronchitis in early childhood. *Lancet* 1974; 2:1031-1034.
89. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of smoking cessation intervention on 14.5 year mortality: a randomized clinical trial. *Ann Intern Med* 2005; 142:233-239.
90. Fione MC, Bailey WC, Cohen SJ. Smoking cessation; Information for specialists. Rockville MD: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research and Centers for Disease Control and Prevention;1996.
91. Malaysian Clinical Practice Guideline on Treatment of Tobacco Use and Dependence 2003. Available at www.moh.gov.my/MohPortal/DownloadServlet?id=375&type=2. Accessed: 7 September 2009.
92. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff and Consortium Representatives. A clinical practice guideline for treating tobacco use and dependence. *JAMA* 2000; 28:3244-3254.
93. Baillie AJ, Mattick RP, Hall W, et al. Meta-analytic review of the efficiency of smoking cessation interventions. *Drug Alcohol Rev* 1994; 13:157-170.
94. Wilson DH, Wakefield MA, Steven ID, et al. "Sick of Smoking"; evaluation of a targeted minimal smoking cessation intervention in general practice. *Med J Aust* 1990; 152:518-521.
95. Britton J, Knox A. Helping people to stop smoking: the new smoking cessation guidelines. *Thorax* 1999; 54:1-2.
96. American Medical Association. Guidelines for the diagnosis and treatment of nicotine dependence: how to help patients stop smoking. Washington DC; American Medical Association, 1994.
97. Tashkin D, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double blind placebo controlled, randomized trial. *Lancet* 2001; 357:1571-1575.
98. Lancaster T, Stead L, Silagy C, et al. Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. *BMJ* 2000; 321:355-358.
99. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained release bupropion, a nicotine patch, or both for smoking cessation. *N Engl J Med* 1999; 340:685-691.
100. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained release bupropion for smoking cessation: a randomized controlled trial. *JAMA* 2006; 296:56-63.
101. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. *Cochrane Database of Systematic Reviews* 2008, Issue 1. Art. No.: CD006103. DOI: 10.1002/14651858.CD006103.pub3
102. Chapman RS, He X, Blair AE, et al. Improvement in household stoves and risk of chronic obstructive pulmonary disease in Xuanwei, China: retrospective cohort study. *Br Med J* 2005; 331:1050.
103. Ghambarian MH, Feenstra TL, Zwanikken P, et al. Can prevention be improved? Proposal for an integrated intervention strategy. *Prev Med* 2004; 39:337-343.
104. Nichter M. Introducing tobacco cessation in developing countries: an overview of Quit Smoking International. *Tab Control* 2006; 15:12-17.
105. Ackermann-Lieblich U, Leuenbenger P, Schwartz J, et al. Lung function and long term exposure to air pollutants in Switzerland. Study on Air Pollution and Lung Diseases in Adults (SAPALDIA) Team. *Am J Respir Crit Care Med* 1997; 155:122-129.
106. Stewart MA. Effective physician-patient communication and health outcomes: a review. *CMAJ* 1995; 152:1423-1433.
107. Clark NM, Nothwehr F, Gong M, et al. Physician-patient partnership in managing chronic illness. *Acad Med* 1995; 70:957-959.
108. Celli BR. Pulmonary rehabilitation in patients with COPD. *Am J Respir Crit Care Med* 1995; 152: 861-864.
109. Janelli LM, Scherer YK, Schmieder LE. Can a pulmonary health teaching program alter patients' ability to cope with COPD? *Rehabil Nurs* 1991; 16:199-202.
110. Ashikaga T, Vacek PM, Lewis SO. Evaluation of a community-based education program for individuals with chronic obstructive pulmonary disease. *J Rehabil* 1980; 46:23-52.
111. Toshima MT, Kaplan RM, Ries AL, et al. Experimental evaluation of rehabilitation in chronic obstructive pulmonary disease: short-term effects on exercise endurance and health status. *Health Psychol* 1990; 9:237-252.
112. Heffner JE, Fahy B, Hilling L, et al. Outcomes of advance directive education of pulmonary rehabilitation patients. *Am J Respir Crit Care Med* 1997; 155:1055-1099.
113. Adams SG, Smith PK, Allan PF, et al. Systematic review of the chronic care model in chronic obstructive pulmonary disease prevention and management. *Arch Intern Med* 2007; 167:551-561.
114. Bourbeau J, Julien M, Maltais F, et al. Reduction of hospital utilisation in patients with chronic obstructive pulmonary disease: a disease-specific self management intervention. *Arch Intern Med* 2003; 163:585-591.
115. Poole P, Chacko EE, Wood-Baker R, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 2006, Issue 1. Art. No.: CD002733. DOI: 10.1002/14651858.CD002733.pub2.
116. Nichol K, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalizations and mortality among elderly patients with chronic lung disease. *Ann Intern Med* 1999; 130:397-403.

117. Wongsurakiat P, Maranetra KN, Wasi C, et al. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: A randomized controlled study. *Chest* 2004; 125:2011-2020.
118. Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. *JAMA* 1993; 270:1826-1831.
119. Alfageme I, Vazquez R, Reyes N, et al. Clinical efficacy of antipneumococcal vaccination in patients with COPD. *Thorax* 2006; 61:189-195.
120. World Health Organization. Available at <http://www.who.int/vaccines/en/pneumococcus.shtml>. Accessed 31 August 2009.
121. Sestini P, Renzoni E, Robinson S, Poole P. Short-acting beta2-agonists for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2002, Issue 2. Art. No.: CD001495. DOI: 10.1002/14651858.CD001495.
122. Ikeda A, Nishimura K, Koyama H, et al. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD - comparison with ipratropium bromide alone. *Chest* 1995; 107:401-405.
123. Keda A, Nishimura K, Koyama H, et al. Comparative dose-response study of 3 anticholinergic agents and fenoterol using a metered-dose inhaler in patients with chronic obstructive pulmonary-disease. *Thorax* 1995; 50:62-66.
124. Rennard SI, Anderson W, ZuWallack R, et al. Use of a long-acting inhaled beta(2)-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. *Am J Resp Crit Care Med* 2001; 163:1087-1092.
125. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. *Chest* 1999; 115:957-965.
126. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. *Chest* 1994; 105:1411-1419.
127. Appleton S, Poole P, Smith B, et al. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD001104. DOI: 10.1002/14651858.CD001104.pub2
128. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. *N Engl J Med* 2007; 356:775-789.
129. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. *Eur Respir J* 2002; 19:217-224.
130. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. *Eur Respir J* 2002; 19:209-216.
131. Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. *Eur Respir J* 2006; 27:547-555.
132. Casaburi R, Briggs DD Jr, Donohue JF, et al. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. *Chest* 2000; 118:1294-1302.
133. Tashkin DP, Celli B, Senn S, et al. A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease Volume. *N Eng J Med* 2008; 359:1543-1554.
134. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. *Chest* 2002; 122:47-55.
135. Van Noord JA, Aumann J, Janssens E, et al. Comparison of tiotropium qd, formoterol bid and both combined qd in patients with COPD. *Eur Respir J* 2005; 26:214-222.
136. Van Noord JA, Aumann JL, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. *Chest* 2006; 129:509-517.
137. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. *Ann Intern Med* 2007; 146:545-555.
138. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. *Am J Resp Crit Care Med* 2002; 166:1084-1091.
139. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. *Eur Resp J* 2003; 21:74-81.
140. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial. *Lancet* 2003; 361:449-456.
141. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. *Am J Respir Crit Care Med* 2008; 178:332-338.
142. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. *Am J Respir Crit Care Med* 2008; 177(1):19-26.
143. Pauwels RA, Lofdahl, C, Laitinen, LS, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. *N Engl J Med* 1999; 340:1948-1953.
144. Vestbo J, Sorensen, T, Lange, P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease; a randomised controlled trial. *Lancet* 1999; 353:1819-1823.

145. Burge PS, Calverley PMA, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. *BMJ* 2000; 320:1297-1303.
146. Paggiaro PL, Dahle R, Bakran I, et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. *Lancet* 1998; 351:773-780.
147. Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease. A meta-analysis. *Ann Intern Med* 1991; 114:216-223.
148. Schols AM, Wesseling, G, Kester, AD, et al Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids. *Eur Respir J* 2001; 17:337-342.
149. ZuWallack RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. *Chest* 2001; 119:1661-1670.
150. Barnes PJ, Stockley RA. COPD: current therapeutic interventions and future approaches. *Eur Respir J* 2005; 25:1084-1106.
151. Culpitt SV, de Matos C, Russell RE, et al. Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in COPD. *Am J Respir Crit Care Med* 2002; 165:1371-1376.
152. Kobayashi M, Nasuhara Y, Betsuyaku T, et al. Effect of low-dose theophylline on airway inflammation in COPD. *Respirology* 2004; 9:249-254.
153. Cosio BG, Tsaprouni L, Ito K, et al. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. *J Exp Med* 2004; 200:689-695.
154. Barnes PJ, Ito K, and Adcock IMA mechanism of corticosteroid resistance in COPD: inactivation of histone deacetylase. *Lancet* 2004; 363:731-733.
155. Ito K, Lim S, Caramori G, et al. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression and inhibits glucocorticoid actions in alveolar macrophages. *FASEB J* 2001; 15:1100-1102.
156. Calverley PMA, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. *Lancet* 2009; 374:685-694.
157. Fabbri LM, Calverley PMA, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long-acting bronchodilators: two randomised clinical trials. *Lancet* 2009; 374:695-703.
158. Rennard SI, Schachter N, Strek M, et al. Cilomilast for COPD. *Chest* 2006; 129:56-66.
159. American Thoracic Society/European Respiratory Society Statement on Pulmonary Rehabilitation. *Am J Respir Crit Care Med* 2006; 173:1390-1413.
160. The effectiveness of pulmonary rehabilitation: evidence and implications for physiotherapists. Chartered Society Physiotherapy 2003
161. Ries AL, Bauldoff GS, Carlin BW, et al. Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. *Chest* 2007; 131:4S-42S.
162. Maltais F, Bourbeau J, Shapiro S, et al. Effects of home-based pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. *Ann Intern Med* 2008; 149:869-878.
163. du Moulin M, Taube K, Wegscheider K, et al. Home-based exercise training as maintenance after outpatient pulmonary rehabilitation. *Respiration* 2009; 77:139-145.
164. Stribos JH, Postma DS, van Altena R, et al. A comparison between an outpatient hospital-based pulmonary rehabilitation program and a home-care pulmonary rehabilitation program in patients with COPD. A follow-up of 18 months. *Chest* 1996; 109:366-372.
165. Na JO, Kim DS, Yoon SH, et al. A simple and easy home-based pulmonary rehabilitation programme for patients with chronic lung diseases. *Monaldi Arch Chest Dis* 2005; 1:30-36.
166. Wijkstra PJ, van der Mark TW, Kraan J, et al. Effects of home rehabilitation on physical performance in patients with chronic obstructive pulmonary disease (COPD). *Eur Respir J* 1996; 9:104-110.
167. Ramli A, Manap RA, Joseph L. Perbandingan antara rehabilitasi pulmonari di rumah dengan di hospital bagi pesakit COPD dalam memperbaiki status fungsi paru-paru. *Malaysian Journal of Health Sciences* 2008; 6: 95-108.
168. Cambach W, Chadwick-Straver RVM, Wagenaar RC, et al. The effects of a community-based pulmonary rehabilitation programme on exercise tolerance and quality of life: a randomized controlled trial. *Eur Respir J* 1997; 10:104-113.
169. Lacasse Y, Guyatt GH, Goldstein RS. The components of a respiratory rehabilitation program: a systematic overview. *Chest* 1997; 111:1077-1088.
170. Cambach W, Wagenaar RC, Koelman TW, et al. The long-term effects of pulmonary rehabilitation in patients with asthma and chronic obstructive pulmonary disease: a research synthesis. *Arch Phys Med Rehab* 1999; 80:103-111.
171. Lacasse Y, Wong E, Guyatt GH, et al. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. *Lancet* 1996; 348:1115-1119.
172. Report of the Medical Research Council Working Party. Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. *Lancet* 1981; 1:681-686.

173. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxaemic chronic obstructive lung disease. *Ann Intern Med* 1980; 93:391–398.
174. Cranston JM, Crockett A, Moss J, et al. Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD001744. DOI: 10.1002/14651858.CD001744.pub2
175. Guyatt GH, Nonoyama M, Lacchetti C, et al. A randomized trial of strategies for assessing eligibility for long-term domiciliary oxygen therapy. *Am J Respir Crit Care Med* 2005; 172:573–580.
176. Schols AM and Wouters EF. Nutritional abnormalities and supplementation in COPD. *Clin Chest Med* 2000; 21:753-762.
177. Landbo C, Prescott E, Lange P, et al. Prognostic value of nutritional status in COPD. *Am J Resp Crit Care Med* 1999; 160:1856-1861.
178. Vestbo J, Prescott E, Almdal T, et al. Body mass, fat-free body mass and prognosis in COPD patients from a random population sample. *Am J Resp Crit Care Med* 2006; 173:79-83.
179. Ferreira IM, Brooks D, Lacasse Y, et al. Nutritional supplementation for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2005; Issue 2. Art.No.:CD000998. DOI: 10.1002/14651858.CD000998.pub2.
180. Ferreira IM. Update nutritional support for patients with COPD. *Respiratory Medicine: COPD Update* 2008; 4:127-131.
181. Suzana S, Harris MY, Tang SY, Roslina AM Changes in nutritional, functional status and quality of life of COPD out-patients after a pulmonary rehabilitation programme in HUKM: a pilot study. *Malaysian Journal of Nutrition* 2008; 14:151-162
182. Fishman, A, Martinez, F, Naunheim, K, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. *N Engl J Med* 2003; 348:2059-2073.
183. National Emphysema Treatment Trial Research Group. Patients at high risk of death after lung-volume-reduction surgery. *N Engl J Med* 2001; 345:1075-1083.
184. Schipper PH, Meyers BF, Battafarano RJ, et al. Outcomes after resection of giant emphysematous bullae. *Ann Thorac Surg* 2004; 78:976-982.
185. Noppen M, Tellings JC; Dekeukeleire T, et al. Successful treatment of a giant emphysematous bulla by bronchoscopic placement of endobronchial valves *Chest* 2006; 130:1563-1565.
186. Sahi H, Demet Karnak D, Meli YM, et al. Bronchoscopic Approach to COPD. *COPD: Journal of Chronic Obstructive Pulmonary Disease* 2008; 2:25-131.
187. Orens, JB, Estenne, M, Arcasoy, S, et al. International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant* 2006; 25:745-755.
188. Studer, SM, Levy, RD, McNeil, K, et al. Lung transplant outcomes: a review of survival, graft function, physiology, health-related quality of life and cost effectiveness. *Eur Respir J* 2004; 24:674-685.
189. de Perrot, M, Chaparro, C, McRae, K, et al. Twenty-year experience of lung transplantation at a single center: Influence of recipient diagnosis on long-term survival. *J Thorac Cardiovasc Surg* 2004; 127:1493-1501.
190. McAlister, FA, Khan, NA, Straus, SE, et al. Accuracy of the preoperative assessment in predicting pulmonary risk after nonthoracic surgery. *Am J Resp Crit Care Med* 2003; 167:741-744.
191. McAlister FA, Bertsch K, Man J, et al. Incidence of and risk factors for pulmonary complications after non-thoracic surgery *Am J Resp Crit Care Med* 2005; 171:514-517.
192. Fisher BW, Majumdar SR, McAlister FA. Predicting pulmonary complications after nonthoracic surgery: a systematic review of blinded studies. *Am J Med* 2002; 112:219–225.
193. Kroenke K, Lawrence VA, Theroux JF, et al. Postoperative complications after thoracic and major abdominal surgery in patients with and without obstructive lung disease. *Chest* 1993; 104:1445-1451.
194. Fuster RG, Argudo JA, Albarova OG, et al. Prognostic value of chronic obstructive pulmonary disease in coronary artery bypass grafting. *Eur J Cardiothorac Surg* 2006; 29:202-209.
195. Schuurmans MM, Diacon AH, Bolliger CT. Functional evaluation before lung resection. *Clin Chest Med* 2002; 23: 159-172.
196. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. *Eur Resp J* 2004; 23:932-946.
197. Nakagawa M, Tanaka H, Tsukuma H, et al. Relationship between the duration of the preoperative smoke-free period and the incidence of postoperative pulmonary complications after pulmonary surgery. *Chest* 2001; 120:705-710.
198. Bingol H, Cingoz F, Balkan A, et al. The effect of oral prednisolone with chronic obstructive pulmonary disease undergoing coronary artery bypass surgery. *J Card Surg* 2005; 20:252-256.
199. Starobin D, Kramer MR, Garty M, et al. Morbidity associated with systemic corticosteroid preparation for coronary artery bypass grafting in patients with chronic obstructive pulmonary disease: a case control study. *J Cardiothorac Surg* 2007; 2:25. doi: 10.1186/1749-8090-2-25.
200. Warner DO. Improving postoperative respiratory outcome. Presented at: Euroanaesthesia, European Society of Anaesthesiology; Vienna, Austria: May 2005. Accessed July 20, 2009.

201. Qaseem A, Snow V, Fitterman N, et al: Risk assessment for and strategies to reduce perioperative pulmonary complications for patients undergoing noncardiothoracic surgery: a guideline from the American College of Physicians. *Ann Intern Med* 2006; 144:575-580.
202. Smetana GW, Lawrence VA, Cornell JE. Preoperative pulmonary risk stratification for noncardiothoracic surgery: systematic review for the American College of Physicians. *Ann Intern Med* 2006; 144:581-595.
203. Bapojie SR, Whitaker JF, Schulz T, et al. Preoperative Evaluation of the Patient With Pulmonary Disease *Chest* 2007; 132:1637-1645
204. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2007 update. *Can Respir J* 2007; 14(Suppl 5):5B-32B.
205. Fletcher CM, Peto R, Tinker CM, et al. Natural history of chronic bronchitis and emphysema. Oxford: Oxford University Press; 1976.
206. Wouters EF. The burden of COPD in The Netherlands: results from the Confronting COPD survey. *Respir Med* 2003; 97:S51-S59.
207. Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. *Thorax* 2002; 57:847-852.
208. Kessler R, Stahl E, Vogelmeier C, et al. Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. *Chest* 2006; 130:133-142.
209. Seemungal TA, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2000; 161:1608-1613.
210. Au DH, Bryson CL, Chien JW, et al. The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations. *J Gen Intern Med* 2009; 24:457-463.
211. Godtfredsen NS, Vestbo J, Osler M, Prescott E. Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. *Thorax* 2002; 57:967-972.
212. Wedzicha JA. Role of viruses in exacerbations of chronic obstructive pulmonary disease. *Proc Am Thorac Soc* 2004; 1:115-120.
213. Hutchinsonson AF, Ghimire AK, Thompson MA, et al. A community-based, time-matched, case-control study of respiratory viruses and exacerbations of COPD. *Respir Med* 2007; 101:2472-2481.
214. Ko FWS, Tam W, Wong TW, et al. Temporal relationship between air pollutants and hospital admissions for chronic obstructive pulmonary disease in Hong Kong. *Thorax* 2007; 62:780-785.
215. Barnes, PJ. Chronic Obstructive Pulmonary Disease. *N Engl J Med* 2000; 343:269-280.
216. Sapey E, Stockley RA. COPD exacerbations: Aetiology. *Thorax* 2006; 61:250-258.
217. Sethi S. Bacterial Infection and the pathogenesis of COPD. *Chest* 2000; 117:380S-385S.
218. Alamoudi OS. Bacterial infection and risk factors in outpatients with acute exacerbation of chronic obstructive pulmonary disease: A 2-year prospective study. *Respirology* 2007; 12:283-287.
219. Lin SH, Kuo PH, Hsueh PR, et al. Sputum bacteriology in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease in Taiwan with an emphasis on *Klebsiella pneumoniae* and *Pseudomonas aeruginosa*. *Respirology* 2007; 12:81-87.
220. Tillie-Leblond I, Marquette CH, Perez T, et al. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: Prevalence and risk factors. *Ann Intern Med* 2006; 144:390-396.
221. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. *Respir Care* 2003; 48:1204-1212.
222. Xu W, Collet JP, Shapiro S, et al. Independent effect of depression and anxiety on chronic obstructive pulmonary disease exacerbations and hospitalizations. *Am J Respir Crit Care Med* 2008; 178:913-920.
223. Okubadejo AA, O'Shea L, Jones PW, et al. Home assessment of activities of daily living in patients with severe chronic obstructive pulmonary disease on long-term oxygen therapy. *Eur Respir J* 1997; 10:1572-1575.
224. Leung J, Duffy M. Chronic obstructive pulmonary disease. In: Peter Cameron, George Jelinek, Anne-Maree Kelly, Lindsay Murray, Anthony FT Brown eds. *Textbook of Adult Emergency Medicine* 3rd Ed. Churchill Livingstone, Elsevier. 2009: 298-303.
225. Roche N, Kouassi B, Rabbat A, et al. Yield of sputum microbiological examination in patients hospitalised for exacerbations of chronic obstructive pulmonary disease with purulent sputum. *Respiration* 2007; 74:19–25.
226. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. *Ann Intern Med* 1987; 106:196-204.
227. Turner MO, Patel A, Ginsberg S, et al. Bronchodilator delivery in acute airflow obstruction. A meta analysis. *Arch Intern Med* 1997; 157:1736–44.
228. Thompson WH, Nielson CP, Carvalho P, et al. Controlled trial of oral prednisolone in outpatients with acute chronic obstructive disease pulmonary disease exacerbations. *Am J Respir Crit Care Med* 1996; 154:407-412
229. Miller RF, O'Doherty MJ. Nebulisers for patients with HIV infection and AIDS. *Thorax* 1996; 52(Suppl 2):S60-S63.
230. Mahon JI, Laupacis A, Hodder RV, et al. Theophylline for irreversible chronic airflow limitation: a randomised study comparing n of 1 trials to standard practice. *Chest* 1999; 115:38-48.

231. Davies L, Angus RM, Calverly PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. *Lancet* 1999; 354:456-460.
232. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. *N Engl J Med* 1999; 340:1941-1947.
233. Maltais F, Ostinelli J, Bourbeau J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations. *Am J Respir Crit Care Med* 2002; 165:698-703.
234. Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta analysis. *JAMA* 1995; 273:957-960.
235. Grossman RF. The value of antibiotics and the outcomes of antibiotic therapy in exacerbation of COPD. *Chest* 1998; 113:249S-55S.
236. Nouira S, Marghli S, Belghith M, et al. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbations requiring mechanical ventilation: a randomized controlled trial. *Lancet* 2001; 358:2020-2025.
237. Malaysian National Antibiotic Guidelines. Available at [http://www.pharmacy.gov.my/aeimages/File?National_Antibiotic_Guideline_2008_edit\(2\).pdf](http://www.pharmacy.gov.my/aeimages/File?National_Antibiotic_Guideline_2008_edit(2).pdf). Accessed: 3 September 2009.
238. Thromboembolic Risk Factors Consensus Group. Risk and prophylaxis for venous thromboembolism in hospital patient. *BMJ* 1992; 82:127-137.
239. Ambrosetti M, Ageno W, Spanevello A, et al. Prevalence and prevention of venous thromboembolism in patients with acute exacerbations of COPD. *Thromb Res* 2003; 112:203-207.
240. Schols AM, Slangen J, Volovics L, et al. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1998; 157:1791-1797.
241. Siafakas NM and Bouros D, Management of acute exacerbation of chronic obstructive pulmonary disease, in Management of Chronic Obstructive Pulmonary Disease, D. Postma and Siafakas NM, Editors. 1998, ERS Monograph: Sheffield. p. 264-277.
242. Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. *N Engl J Med* 1995; 333:817-822.
243. National Association for Medical Direction of Respiratory Care, Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation--a consensus conference report. *Chest* 1999; 116:521-534.
244. Sin DD, Bell NR, Swenson LW, et al. The impact of follow-up physician visits on emergency readmissions for patients with asthma and chronic obstructive pulmonary disease: a population-based study. *Am J Med* 2002; 112:120-125.
245. U.S. Preventive Services Task Force. Screening for chronic obstructive pulmonary disease using spirometry: U.S. Preventive Services Task Force Recommendation Statement. *Ann Intern Med* 2008; 148:529-534.
246. U.S. Preventive Services Task Force. Counseling and Interventions to Prevent Tobacco Use and Tobacco- Caused Disease in Adults and Pregnant Women: U.S. Preventive Services Task Force Reaffirmation Recommendation Statement. *Ann Intern Med* 2009; 150:551-555.
247. Asia Pacific COPD Roundtable Group. Global Initiative for Chronic Obstructive Lung Disease strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: an Asia-Pacific perspective. *Respirology* 2005; 10:9-17.

LEVELS OF EVIDENCE SCALE

The definition of levels of evidence and the grading of recommendations used in these guidelines are shown in the following tables:

I	Evidence obtained from at least one properly randomized controlled trial
II - 1	Evidence obtained from well-designed controlled trials without randomization
II - 2	Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one center or research group
II - 3	Evidence obtained from multiple time series with or without intervention. Dramatic results in uncontrolled experiments (such as the results of the introduction of penicillin treatment in the 1940s) could also be regarded as this type of evidence
III	Opinions of respected authorities, based on clinical experience; descriptive studies and case reports; or reports of expert committees

SOURCE: U.S./CANADIAN PREVENTIVE SERVICES TASK FORCE

GRADES OF RECOMMENDATIONS

A	At least one meta analysis, systematic review, or RCT, or evidence rated as good and directly applicable to the target population
B	Evidence from well conducted clinical trials, directly applicable to the target population, and demonstrating overall consistency of results; or evidence extrapolated from meta analysis, systematic review, or RCT
C	Evidence from expert committee reports, or opinions and/or clinical experiences of respected authorities; indicates absence of directly applicable clinical studies of good quality

SOURCE: MODIFIED FROM SCOTTISH INTERCOLLEGIATE GUIDELINES NETWORK (SIGN)